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ABSTRACT/KURZBESCHREIBUNG 
 The present work is based on the synthesis of novel oxygen containing and 
nitrogen containing heterocycles. A simple and convenient domino cycloaromatization 
approach towards the synthesis of novel benzo[c]chromen-6-ones and 
benzo[c]chromenes by treatment of heterocyclic chlorovinyl-aldehydes with active 
methylene compounds has been developed. In another strategy novel biaryl lactones 
were prepared by Sonogashira cross-coupling and base catalyzed reactions of 4-chloro-
2-oxo-2H-chromene-3-carbaldehyde with terminal alkynes and 1, 3-dicarbonyl 
compounds. Finally some heterocyclic chlorovinyl-aldehydes were treated with 
electron rich heterocyclic amines to afford novel heteroannulated pyrrolo and pyrazolo 
pyridines. 
 Die vorliegende Arbeit basiert auf der Synthese neuer Sauerstoff- und 
Stickstoffheterozyklen. Ein einfacher und zugleich praktischer Ansatz zur Synthese 
bisher unbekannter benzo[c]chromen-6-onen und Benzo[c]Chromenen wurde 
entwickelt. Die Umsetzung von heterozyklischen Chlorvinyl-Aldehyden mit CH-
aziden Verbindungen führte in einer Domino-Zyklisierungs-Aromatisierungs Sequenz 
zu den entsprechenden Produkten. 
 Weiterhin wurden neue Biaryllaktone mittels Sonogashira-Reaktion und 
anschließender basenkatalysierter Reaktion von 4-Chlor-2-oxo-2H-Chromene-3-
Carbaldehyd, terminalen Alkinen und 1,3-Dicarbonylverbindungen synthetisiert. 
Abschließend gelang die Synthese bisher unbekannter heterozyklisch verknüpfter 
Pyrrolpyridine und Pyrazolpyridine durch Umsetzung heterozyklischer Chlorvinyl-
aldehyde mit elektronenreichen, heterozyklischen Aminen. 
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1. Heterocyclic chlorovinyl-aldehydes 
1.1 General introduction and synthesis 
 Heterocyclic chlorovinyl-aldehydes are important and versatile molecular building 
blocks for the synthesis of variety of organic compounds with interesting biological 
and physico-organic properties. These building blocks were appeared first in the 
scientific literature following the advent of famous Vilsmeier-Haack reagent 
(POCl3+DMF) in 1927
1. One key aspect of this reagent is that depending on the nature 
of reacting substrates, it could introduce chloro-formyl functionality in the product 
skeleton. In 1958 Arnold and Zemlicka first reported the synthesis of β-chloro-
acroleins when they treated POCl3 and DMF with enolizable ketones.
2 Later on the 
Vilsmeier-Haack chloro-formylation reactions were employed to cyclic substrates 
bearing keto methylene functionality, which resulted heteocyclic chlorovinyl-aldehydes 
successfully.3-6 A general mechanistic scheme of the reaction is given in figure 1. 
 
Figure 1. A general mechanism for the synthesis of heterocyclic chlorovinyl-aldehydes 
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1.2 Synthetic scope of heterocyclic chlorovinyl-aldehydes 
 Heterocylic chlorovinyl-aldehydes act as ambident elecrophiles because of the 
presence of formyl functionality and an activated chloro group, therefore easily 
undergo variety of cyclization reactions with compounds possessing bis-nucleophilic 
properties. A graphical overview of heterocyclization reactions of chlorovinyl-
aldehydes is given in figure 2.7-14 
 
Figure 2. Synthetic utility of some selected heterocyclic chlorovinyl-aldehydes. 
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 The heterocyclized products obtained from chlorovinyl-aldehydes have been 
evaluated against variety of biological protocols and are known to possess anti-
bacterial, anti-oxidant and anticancer activities. Literature survey revealed that many 
researchers have employed different synthetic strategies on these organic substrates and 
have constructed interesting heterocylic systems with remarkable pharmaceutical and 
photo-physical properties. These methodologies involved, multistep synthesis based on 
function group transformations, metal catalyzed cross-coupling reactions and 
subsequent annulations reactions, multi-component reactions and domino-cyclization 
reactions etc. Ray et al.15 have described a multistep synthesis of antitumor poly cyclic 
oxa-coumarins from chloroaldehyde derivatives. Stephanie Hesse and Gilbert Krisch 
have studied Suzuki cross-coupling reactions with β-chloroacroleins, subsequent ring 
closure of Suzuki products to δ-lactone gave heterocycles bearing a coumarinic 
moiety.9In another report Ding-Yah Yang and co-workers have synthesized two light 
sensitive pyranocoumarins via multicomponent condensation of chloro-aldehyde 
coumarin and 4-methyl quinolines.16 
1.3 Annulation reactions of heterocyclic chlorovinyl-aldehydes: Present work 
 As we have seen that hetero-annulation reactions of heterocyclic chlorovinyl-
aldehydes are quite common in scientific literature. Nonetheless, there is a domain of 
carbocylcoaromatization reactions of these building blocks that still requires attention 
of synthetic chemists. Efficient protocols for the benzoannulation of heterocyclic 
chlorovinyl-aldehydes are relatively rare. Only few reports related to benzoannulation 
reactions of cyclic β-bromovinyl-aldehydes are available. Ray et al17 have synthesized 
substituted benzene derivatives employing base-catalyzed and water mediated 
cycloaromatization reactions of cyclic β-bromovinyl-aldehydes with β-ketoesters. The 
mechanism involved classical Knoevenagel type cyclocondensation reaction. In 
another synthetic approach transition metal catalyzed aromatization using tendem Heck 
and aldol reactions were employed for the construction of carbocylic skeleton on the 
simple aromatic β-bromovinyl-aldehydes.18 These findings could instigate one to 
employ similar benzoannulation approaches to heterocyclic chlorovinyl-aldehydes 
substrates that may finally lead to the synthesis of novel biologically active 
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benzoannulated heterocycles. In view of above literary findings a general layout of the 
current work on heterocylic chlorovinyl-aldehydes is given in figure 3. 
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Figure 3. Layout for the synthesis of benzoannulated and heteroannulated heterocycles 
 In the present work four heterocyclic chlorovinyl-aldehyde building blocks were 
selected for their further reactions with nucleophilic reagents.  
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Figure 4. Synthesis of some heterocyclic cholorvinyl-aldehyde building blocks. 
 These molecular building blocks namely 4-chloro-2-oxo-2H-chromene-3-
carbaldehyde (1), 4-chloro-2H-chromene-3-carbaldehyde (2), 4-chloro-2-phenyl-2H-
chromene-3-carbaldehyde (3) and 4-chloroquiniline-3-carbaldehyde (4) were 
synthesized from their corresponding substrates by well-known Vilsmeier-Haack 
reactions.19-22 (Figure 4). 
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2. One pot synthesis of 6H-benzo[c]chromen-6-ones by 
 cyclocondensation of 1, 3-dicarbonyl compounds with 4-chloro-3-
 formylcoumarin. 
2.1 Introduction  
 Functionalized biaryl lactones(6H-benzo[c]chromen-6-ones or 6H-dibenzo [b,d] 
pyran-6-ones) are found in a variety of important natural productswith considerable 
pharmacological relevance such asfasciculiferol alternariol, autmnariol, autumnariniol 
and altenuisol etc.23,24 Some of their structural analogues with variety of ring 
extensions and functional group substitutions are known to possess enzyme and cell 
growth inhibition, bactericidal and antitumor activities e.g. ellagic acid, gilvocarcins, 
ravidomycins, chrysomycins and arnottin I.25-29 
 
 
 
 
 
 
 
 
      Figure 5. Biaryl lactones natural products and 6H-benzo[c] chromen-6-one 
nucleus). 
 Several strategies for the syntheses of substituted 6H-benzo[c]chromen-6-ones 
have been appeared in the scientific literature. Some of the important approaches 
include cyclization of o-bromobenzoic acid with phenols,30intramolecular Pd (II)-
catalyzed coupling reactions of aryl benzoates,31combination of directed ortho-
O O
OH
HO
HO O O
OH
HO
O O
OH
HO O O
OH
OO
A B
C1
2
3
4
7
8
9
10
 Fasciculiferol  Alternariol
 Ellagic acid  6H-benzo[c]chromen-6-one
- 16 - 
 
metalations (DOM) with subsequent Suzuki cross-coupling reactions etc.26 Few years 
ago, Chan et al. reported salicylates based approach for the synthesis of biaryl lactones 
by formal [3+3] cyclization of 1,3-bis (silyl enol ethers) with 3-siloxy-2-en-1-ones.32 In 
recent years, many cyclization reaction’s strategies were developed for the synthesis of 
novel 6H-benzo[c]chromen-6-ones (7) in the group of Prof. Langer (Figure 6) (for 
clarity reasons substitution pattern is omitted). In one case, treatment of activated 
chromones 5 with 1, 3-bis (silyl enol ethers) gave functionalized 2, 3-dihydrogen 
benzopyrans which on treatment with NEt3 or BBr3 underwent retro-Michael-aldol-
lactonization reactions to give variety of 7-hydroxy 6H-benzo[c]chromen-6-ones.33 
 
Figure 6. Synthesis of 6H-benzo[c]chromen-6-ones (7) ( Langer’s group) 
 In  another strategy, variety of salicylates 6 have been prepared by formal [3+3] 
cyclization of 1,3-bis (silyl enol ethers) with 3-siloxy-2-en-1-ones, suzuki coupling of 
their triflates with o-methoxy boronic acids and subsequent BBr3-mediated 
lactonization afforded flora of novel 6H-benzo[c]chromen-6-ones .34 Moving forward 
on the same lines in Langer’s lab, functionalized 9-hydroxy-6H-benzo[c]chromen-6-
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ones have been prepared by cyclization of 1,3-bis (silyloxy)-1,3-butadienes with easily 
synthesized 4-cholor-3-formylcoumarin (4-chloro-2-oxo-2H-chromene-3-
carbaldehyde) (1).35 Recently Bodwell et al. employed an efficient multicomponent 
(MCR) technique for the synthesis of 6H-benzo[c]chromen-6-ones.36 
 A critical study of above mentioned synthesis however reveals the fact that more or 
less each reported synthetic strategy is associated with some synthetic drawbacks such 
as harsh temperature conditions, longer reaction times, lower products yield, use of 
expensive catalyst and difficult purification procedures etc. Presence of these short 
comings may however let down some of the important reported synthetic 
methodologies and if ever be considered by an industry for large scale production of 
these pharmaceutically interesting compounds, an alternatively easier, environmentally 
friendly and direct approach free from any synthetic upheaval will be welcomed 
indubitably. 
 Here in I wish to report a facile one pot synthesis of highly functionalized 6H-
benzo[c]chromen-6-ones by cyclocondensation of 1, 3-dicarbonyl compounds with 4-
chloro-3-formylcoumarin. 
2.2 Results and Discussions 
 The substrate 4-chloro-3-formylcoumarin (1) was easily prepared from 
commercially available 4-hydroxycoumarin by employing well-known Vilsmeier-
Haack reaction.19 
 I treated substrate 1 with 2 equivalent of β-ketoesters 8a-l which underwent 
domino cyclizations to give cyclized products 9a-l in fairly good yields (Scheme 1). 
 Initially I started my work by using K2CO3 as base and DMF as solvent. These 
conditions were successfully employed by Ray and co-workers for the cyclization 
reactions of β-ketoesters with cyclic β-bromovinylaldehydes to achieve the synthesis of 
substituted benzene derivatives.17Unfortunately, with these conditions; I met with 
limited success and got low product yields. I also experienced difficult extraction 
workup because of high boiling point of DMF solvent and its highly polar nature. 
However, changing the solvent to THF gave me highly acceptable results.  
- 18 - 
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Scheme 1. Synthesis of 9a-l. Reagents and conditions: (i) 1 (0.5 mmol), 8a-l (1 mmol) 
K2CO3 (2.0 equiv.), THF 7-8 mL, 50 °C, 4-8 hrs. 
When I treated substrate 1 with methylacetoacetate (8a) by employing THF as solvent 
and K2CO3as base, i got the desired product 9a in 75% yield. The structure of 9a was 
independently confirmed by X-ray crystal structure analysis (Figure 7). 
 
Figure 7. Ortep plot of compound 9a 
 No results were obtained when triethylamine was used as base. Following these 
conditions, products 9a-l were prepared in 45-77% yield by cyclization of 1 with β-
ketoesters 8a-l (Table 1). The reaction times had to be adjusted for each individual 
reaction and were monitored by TLC after regular intervals. 
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Table 1. Synthesis of products 9a-l 
8,9 R1 R2 Time (hrs) Yield (%)a 
a Me Me 4 75 
b Me iPr 6 72 
c Me Et 6 71 
d Me (CH2)2OMe 8 60 
e Me Allyl 8 76 
f Me CH2Ph 4 62 
g Et Me 4 45 
h CH2Cl Me 4 72 
i CH2Cl Et 4 73 
j Pr Et 5 66 
k Ph Et 8 62 
l CH2OMe Me 6 77 
aYields of isolated products. 
2.2.1 Proposed Mechanism 
 The formation of products 9a-l can be explicated as follows (Scheme 2): the 
Knoevenagel-type reaction37,38of 1 equiv of β-ketoester 8a with4-chloro-2-oxo-2H-
chromene-3-carbaldehyde (1) followed by nucleophilic substitution of the chlorine 
atom by a second equivalent of β-ketoester 8a gave intermediate A.  
A base mediated cyclization afforded intermediate B which subsequently underwent 
cleavage of the acetate (intermediate C) and aromatization. The cyclization proceeds 
by regioselective attack onto the keto group which is more electrophilic than the ester 
group. 
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 In literature the Suzuki reaction of β-bromovinylaldehyde with alkenylboronic 
acids and subsequent Harner-Wadsworth-Emmons reaction and 6π-electrocyclization 
has been reported to give annulated ring systems.39However, such electrocyclization 
reactions require high temperatures and presumably do not account for the formation of 
products 9a-l. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2.Possible reaction mechanism for the formation of 9a 
 Some important deviations in products formation have also been noted e.g. when 
substrate 1 was treated with β-ketoester methyl-3-oxopentanoate (8g), I got the desired 
product 9g in 45%, and a by-product 9g’ in 30% yield (Scheme 3).  
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Scheme 3. Synthesis of 9g and 9g’.Reagents and conditions: (i) 1 (0.5 mmol), 8g (1 
   mmol), K2CO3 (2.0 equiv.), THF 7-8 mL, 50 °C, 4 hrs. 
 The formation of side product 9g’ is observed because of decarboxylation of one 
ester side arm during the reaction. The ortep plot of side product 9g’ (Figure 8). 
 
Figure 8. Ortep plot of compound 9g’ 
 I have further studied the scope of reaction by treating dimethyl-3-
oxopentanedioate (10a) and diethyl-3-oxopentanedioate (10b) with substrate 1 
(Scheme 4).  
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O O
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O O
OH OO
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O
RO
 
Scheme 4. Synthesis of 11a and 11b. Reagents and conditions: (i) 1 (0.5 mmol), 10a,  
  b (1 mmol) K2CO3 (2.0 equiv.), THF 7-8 mL, 50 °C, 2 hrs. 
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The reaction successfully afforded 6H-benzo[c]chromen-6-ones 11a and 11b 
bearing hydroxyl functionality on the C ring.   
 The formation of products follows a 1:1 stoichiometry. The reagents 10a and 10b 
bear two nucleophilic parts each bearing acidic protons. The first part may condense 
with the aldehyde group and the other part replaced the chloro group leading to an 
aromatized product. 
 The K2CO3 mediated reaction of 1 with acetylacetone (12) followed a 2:1 
stoichiometry and afforded novel 6H-benzo[c]chromen-6-ones 13 (Scheme 5). 
Me Me
O O
O
Cl
H
O
O
O O
O
i
1 12
13,
(2equiv.)
Me
54 %
 
Scheme 5. Synthesis of 13. Reagents and conditions: (i) 1 (0.5 mmol), 12 (1 mmol), 
K2CO3 (2.0 equiv.), THF 7-8 mL, 50 °C, 4hrs. 
 The structure of 13 was independently confirmed by X-ray crystal structure 
analysis (Figure 9). The formation of product 13 can be explained by mechanism 
similar to the one discussed for the formation of 9g’. 
 
Figure 9. Ortep plot of compound 13 
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2.2.2 Limitations 
 In order to extend the scope of the methodology for the preparation of fluorine 
substituted 6H-benzo[c]chromen-6-ones. I treated substrate 1 with fluorinated 
diketones such as 1, 1, 1-trifluoro-pentane 2, 4-dione and 1, 1, 1 ,5, 5, 5-hexafluoro-
pentane 2,4-dione, but unfortunately, I could not get any desired cyclized product 
(Scheme 6). The reason for unsuccessful reactions of fluorinated β-diketones lies in the 
high electronegativity of fluorine atoms, which make fluorinated β-diketones highly 
reactive nucleophilic species prone to hydration or cleavage in alkaline medium.40 
R CF3
O O
O
Cl
H
O
O
1  (R = Me, CF3)
No reaction
 
Scheme 6. Unsuccessful reactions of substrate 1 with fluorinated diketones. 
2.3 Conclusion 
 In conclusion i have developed a simple and convenient one pot synthesis of 
novel6H-benzo[c]chromen-6-ones by base mediated cyclocondensation of 4-chloro-3-
formyl coumarin with 1, 3-dicarbonyl compounds. Utilizing variety of 1, 3-diketones 
the synthetic scope and limitations were studied in detail. In a nut shell construction of 
C ring of 6H-benzo[c]chromen-6-ones with novel functional group substitution pattern 
has been achieved in a domino fashion. Bio-evaluation of synthesized compounds is in 
progress. 
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3. Base-mediated one pot domino synthesis of 6H-benzo[c]chromenes.
 Study of some structural and physico-organic aspects of newly 
 synthesized products. 
3.1 Introduction. 
 The benzochromene nucleus is found in many heterocyclic biological 
molecules.41In particular, the 6H-benzo[c]chromene is an important molecular scaffold 
of a natural product cannabinol,42whose analogues are known to possess antiemetic, 
analgesic and anticonvulsant properties and may act as selective progesterone receptor 
modulators (SPRM).43-46 (Figure10). 
 
 
 
 
 
Figure 10. Important examples of 6H-benzo[c]chromenes. 
 In literature, different methodologies have been reported for the synthesis of 
substituted 6H-benzo[c]chromenes. Some selected pathways based on underlying 
reaction’s principle are summarized in (Scheme 7). These strategies include metal 
catalyzed coupling reactions,47, 48 intermolecular SN2 reactions,
49 and direct C-H 
functionalization50etc. In the group of Prof. Langer a substrate based strategy has been 
successfully applied for the synthesis of novel 6H-benzo[c]chromenes.51 In this 
methodology an activated chromanone have been treated with substituted 1, 3-
bis(silyloxy)-1,3-butadienes, that underwent [3+3] cyclization to give desired novel 
6H-benzo[c]chromenes. However, despite literary importance these methodologies 
have evolved few synthetic lacking as use of relatively expensive catalysts 
(comparative to inorganic bases), non-benign temperature conditions and worth noting 
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is the non-availability of desired collar of functionalization surrounding 
basicbenzo[c]chromene nucleus that may be required for essential structure-activity 
relationship among other similar classes of heterocyclic compounds. 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 7. Strategies towards the synthesis of 6H-benzo[c]chromenes core 
3.2 Results and Discussions 
 My previous successful findings related to the synthesis of 6H-benzo[c]chromen-6-
ones led me to design a similar series of heterocyclic compounds bearing same 
functionalization onto the C ring. To do this, I have selected substrates 4-chloro-2H-
chromene-3-carbaldehyde (2) and 4-chloro-2-phenyl-2H-chromene-3-carbaldehyde (3). 
(Figure 11). I have synthesized these substrates from their corresponding precursors by 
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famous Vilsmeier-Haack reactions.20, 21For expediency, the chemistry of each substrate 
will be discussed separately. 
 
 
 
 
Figure 11. Chloro substituted chromene-3-carbaldehydes. 
  When I treated substrate 2 with methyl acetoacetate (8a) using K2CO3 as 
base and THF as solvent at room temperature, I could not get the desired cyclized 
product. Although a yellow bright spot was observed on TLC plate, which I could not 
purify even by column chromatography. However on maintaining the moisture free 
conditions and heating the reaction mixture between 50-60 °C for about 2 hrs, I 
observed the appearance of another blue spot that allow me to alter the reaction 
partners i.e. base and the solvent. I started trying base K2CO3 with set of solvents such 
as DMF, CH3CN and toluene but could not observe any appreciable change. However 
on changing the base from K2CO3 to Cs2CO3 and using solvent DMF, I was able to 
isolate the desired cyclized product in only 2% yield (Scheme 8). 
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     Scheme 8. Synthesis of 14a-c, e, m. Reagents and conditions: (i) 2 (1 mmol), 8a-c,  
 e, m (2 mmol), Cs2CO3 (2.0 equiv.), DMF 7-8 mL, 50 °C, 2-4 hrs. 
 No reaction was observed, when organic bases such as triethyl amine, Pepperidine 
and morpholine were used. Fortunately, using the β-ketoester 8c instead of 8a and 
applying Cs2CO3-DMF base-solvent conditions, I have been successfully able to isolate 
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the desired cyclized product in 20 % yield (Table 2). I found purification of desired 
products a bit difficult; therefore repeated column chromatography was done in most of 
the cases. A significant role of nature of ester-linkage on the cyclization process has 
been observed e.g. more electron-donating ester part was found to have a positive 
effect on the product yield. Because of experiencing a limiting trend in the products 
yield, I could not reach to manage a certain set of optimized conditions. Rather, I 
twisted my attention to explore the structural and physico-organic aspects of the 
formed products. 
 Fortunately, I was able to grow the crystal of product 14c. A highly strained 
structural frame work of cyclized product was obtained as is revealed by its X-ray 
analysis. Inspite of the fact, that one could guess easily theoretically the strained 
skeletal features of the cyclized product by keeping in view the sp3 carbon of 6H-
benzo[c]chromene in middle ring, it is worth mentioning that results of the physical 
parameters of this newly cyclized product along with their role in comparison with a 
base as decisive factors on the success of reactions have not been communicated 
earlier. The detailed discussion will be made in structural description section separately 
later on. 
Table 2. Synthesis of 6H-benzo[c] chromenes 14a-c, e, m 
8,18 R1 R2 Time(hrs) Yield 14a-c, e, m (%)a 
a Me Me 4 < 2 
b Me iPr 4 31 
c Me Et 4 22 
e Me Allyl 4 38 
m Me t butyl 4 35 
a Yields of isolated products. 
 I have noticed some interesting observations. When I treated substrate 2 with 
dimethyl acetone-1, 3-dicaroboxylate (10a) in the presence of CS2CO3 and DMF, I got 
15a as a major product in 60 % yield instead of expected cyclized product. By 
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switching over back to conditions using K2CO3 and THF, I got the desired cyclized 
product 16a in 52 % yield along with uncyclized product 15a as minor product in 28 % 
yield (Scheme 9). 
 
 
 
 
 
 
 
Scheme 9. Synthesis of 15 and 16. Reagents and conditions: (i) 2 (1 mmol), 10a (2 
mmol), Cs2CO3 (2.0 equiv.), DMF 7-8 mL, 50 °C, 6 hrs. (ii) 2 (1 mmol), 10a (2 mmol), 
K2CO3 (2.0 equiv.), THF 7-8 mL, 50 °C, 6 hrs. 
 I have selected the right conditions suitable for the formation of cyclized products 
with OH functionality on ring C and prepared three examples in fairly good yields. 
(Table 3). 
Table 3. Synthesis of6H-benzo[c]chromenes 16a-c 
8,18 R1 Time(hrs) Yield 16a-c (%)a 
a Me 6 52 
b Et 6 65 
c tbutyl 6 62 
a Yields of isolated products. 
 Nevertheless, both K2CO3 and Cs2CO3 are relatively strong bases; they behave 
quite differently in organic reactions. The size and softness of cesium cation confer 
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peculiar characteristic to Cs2CO3 thus render it more soluble and reactive in polar 
solvents52. I myself at this stage considered it too early to ascertain the role of two 
different base-solvent systems K2CO3-THF and Cs2CO3-DMF which were found to be 
operated successfully so far. Interestingly when I carried out the reaction of 4-chloro-2-
phenyl-2H-chromene-3-carbaldehyde (3) with dilalkyl-3-oxo-pentanedioates (10a-c) 
using K2CO3 as base and DMF as solvent, i got desirable results (Scheme 10). 
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RR
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i
R = Me, Et, t butyl
 
Scheme 10. Synthesis of 17a-c.Reagents and conditions: (i) 3 (1mmol), 10a-c (2 
mmol), K2CO3 (2.0 equiv.), DMF 7-8 mL, 50 °C, 4 hrs. 
 The yields of the products are given in table 4. Uptill now from my study on the 
reaction of some heterocyclic chlorovinyl-aldehyes with 1, 3-dicarbonyl compounds 
and 1, 3, 5-tricarbonyl compounds, I sorted out three different reaction conditions 
which gave me satisfactory results. The most effective parameters were type of base, 
nature of solvents and nature of substrates. The details of products yield are given in 
(Table 4). 
Table 4.Synthesis of 6H-benzo[c]chromenes 17a-c 
10, 17 R Time (hrs) Yield 17a-c (%)a 
a Me 4 54 
b Et 4 60 
c t- butyl 4 66 
aYields of isolated products. 
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 Unexpectedly, 4-chloro-2-phenyl-2H-chromene-3-carbaldehyde (3) did not show 
any desired reaction with β-ketoesters under any set of reaction conditions I employed 
so far. These findings have finally revealed a decreasing reactivity trend of reactions of 
β-ketoesters with some oxygen containing heterocylic chlorovinyl-aldehydes (Scheme 
11). 
 
 
 
 
 
 
 Scheme11. Reactivity trend of reactions of chloroformyl benzochromenones and 
benzochromenes with β-ketoesters. 
 3.2.1 Structural Description of compound 9c 
 Inorder to discuss X-ray structural aspects of cyclized products, I selected the 
compounds with similar functional group patterns. For that purpose, I first grow the 
crystal of compound 9c (Figure 12). 
 
Figure 12. Ortep plot of compound 9c 
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It serves as standard model for rest of analogous compound possessing similar 
functional group pattern and differ only at one or two position in the rest of skeleton. 
The X-ray structural information shows that over all molecular frame work is 
planar, general parameters includes single bonds between C1-C2 and C3-C4 with 
corresponding bond lengths 1.471 Å and 1.468 Å respectively. Because of aromatic 
character the bond lengths between C2-C3 and C4-C9 are about 1.40 Å. Though ring B 
is almost planar compare to the rest of molecule, however the torsional angle < C1-O1- 
C9 is 121.84 which shows slight deviation from planarity. The bond length between 
C1-O1 is 1.356 Å which is slightly shorter than the bond length between O1-C9 i.e. 
1.381 Å. The bond length between C1-O2 is 1.20 Å that corresponds to double bond. 
The ester side arm attached to C-11 is out of the plane with dihedral angle of 21.02°, 
whereas the other ester side arm attached to C13 shows a higher order of deviation 
from molecular planarity that results a dihedral angle of 81.6°.  
3.2.2 Structural Description of compound 14c 
 
Figure 13. Ortep plot of compound 14c 
 The X-ray crystal structure of compound 14c reveals a highly strained molecular 
framework having all the three fused rings which shows no planarity with respect to 
each other and this is because of the sp3 C-13 of ring B. It gave the ring B a half-chair 
conformation (Figure 13). 
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 The bond length between C13-O1 is 1.4367 Å whereas the bond length between 
O1-C12 is relatively shorter i.e 1.376 Å which justifies half-chair conformation of ring 
B. The bond length between C13-C5 and C6-C7 are 1.498 Å and 1.477 Å respectively. 
The information for the non-linearity of three rings with respect to each other comes 
from the dihedral angles between C5-C6-C7-C12 which 21.74° which slightly have 
more value than the dihedral angle between C1-C6-C7-C8 which is 24.66°. The 
torsional angle between C3-C4-C5-C13 is 175°. The ester side arm attached to C-3 is 
out of the plane with dihedral angle of 21.76°, whereas the other ester side arm attached 
to C1 shows a higher order of deviation from molecular planarity signified by a 
dihedral angle of 86.6°.  
3.2.3 Structural Description of compound 17b. 
 In order to evaluate the effect of substitution on carbon 13 of ring B on structural 
parameter. I need the same compound bearing similar set of functionality pattern, but 
unfortunately I could not get the desired compound. However I was able to get another 
analogue with a hydroxyl functional group on ring C instead of methyl group and a 
phenyl group on carbon atom C9 (Figure 14). 
 The molecule appears to have an overall strained skeleton like that of compound 
14c. The dihedral angle between C1-C6-C7-C8 is 23.54° and between C5-C6-C7-C8 is 
26.37° which are relatively higher than its structural analogue 14c. Likewise the 
torsional angle between C18-C19-C8-C9 is 179.07° which is also slightly higher. The 
single bond lengths between C8-C9 and are found to be 1.51 Å and 1.474 Å 
respectively. The bond-length between C1-O1 is 1.375 which is shorter than the single 
bond length between O1-C9 which is 1.4754 Å. This longer arm makes the C9 out of 
the plane of ring B and confers a strained half-chair conformation. The ester side arm 
attached to carbon16 is found to be out of plane by a dihedral angle of 75.12°. On 
contrary the ester side arm attached to carbon18 is almost planar to main frame by an 
angle of  just 1.05 Å and this is because of hydrogen bonding between hydroxyl group 
and neighboring carbonyl functional group i.e C=O........H-O5 is 1.719 Å. The phenyl 
ring attached to C9 attains a pseudo-perpendicular geometry because of half-chair 
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conformation of C9. The torsional angle between O1-C9-C10-C11 is found to be 51.86 
Å, whereas the dihedral angle between C8-C9-C10-C11 is found to be 168.9 Å. 
 
 Figure 14. Ortep plot of compound 17b 
3.2.4 Mass spectral studies of compound17c 
 Apart from the fact that factors affecting lower yields, like structural strain in the 
newly synthesized 6H-benzo[c]chromenes and the base. I noticed another effect of 
temperature also. The compound 71c is found to be thermally labile as proved by its 
different GC-MS spectrograph from the rest of series of analogous compounds (Figure 
15). 
 The Gas Chromatogram shows two peaks which were appeared later in the mass 
spectrum as molecular ions of masses 274 and 374 respectively that matched exactly of 
the fragments formed after losing ester-side arms of parent molecules while passing 
through gas column (Scheme 12). 
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Figure 15. Gas Chromatogram alongwith Mass spectrum of compound 17c. 
Nevertheless, for compound 17c, appearance of quasi-molecular ion peak at 497 m/z 
(M+Na)+which was observed in ESI-TOF/MassSpectrum that gave another structural 
proof that finally compliment the chain of other structural analyses such as IR, 1HNMR 
and 13CNMR etc. 
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Scheme 12.  Thermal disintegration of compound 17c 
3.2.5 Photophysical studies of selected 6H-benzo[c]chromenes and6H-      
benzo[c]chromen-6-ones 
 Interestingly, 6H-benzo[c]chromenes were found to exhibit UV/Vis and 
fluorescent properties contrary to 6H-benzo[c]chromenes-6-ones which could not 
exhibit fluorescent behavior, so I got the opportunity to measure the UV/VIS and 
fluorescentactivities of some selected 6H-benzo[c]chromenes. The UV/VIS and 
fluorescent spectra are shown in figure 16. 
 The fluorescence measurements were done using established protocols53. The 
UV/VIS spectra have shown that compounds 11a and 11b have same patterns ofmain 
absorption peaks and shoulders because of common biaryl lactone moiety.Similarly 
compounds 14c and 14e possess similar spectral behavior. Compound 16b was found 
to absorb at longer wavelength than rest of the compounds, but its emission spectrum 
lies in between the emission spectra of 11(a,b) and 14 (c,e). The analytical details 
related to UV/VIS and fluorescent properties of 6H-benzo[c]chromenes and 6H-
benzo[c]chromenes-6-ones is summarized in table 5. 
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Figure 16. UV/VIS and fluorescent spectra of 11(a, b), 14 (c, e), 16b. 
Table 5. The UV/VIS and fluorescent measurement data of 11 (a, b), 14 (c, e), 16b. 
compound λabs [nm], εmax ([10
5 M-1 cm-1]) λflu[nm] Quantum Yield (Φflu) 
14c 
228(20140), 280(19800), 
323(14230) 
412 0.489 
14e 
230(14260), 281(16390), 
324(11870) 
414 0.511 
11a 
258(47030), 290(18770), 
316(15550) 
470 0.081 
16b 
228(20500), 287(21640), 
344(17820) 
426 0.411 
11b 256(54790),           319(18700) 466 0.063 
 
 The UV/VIS and fluorescent data in table 5 shows that compound 14c, 14e and 
compound 16b exhibit strong UV-fluorescence as depicted by their relatively high 
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quantum yield values. Comparison of spectral studies between  benzo[c]chromenes and 
benzo[c]chromenones with similar substitution patterns surrounding basic nucleus 
revealed a fact that presence of keto group in the ring B overall inhibits the 
fluorescence activity and it is the biaryl moiety in both kind of compounds that is 
somehow responsible for the fluorescence emission activity. A detailed study of effect 
of ring C substituents onthe fluorescence emission of benzo[c]chromenes and 
benzo[c]chromenones, one could draw out a meaningful statistical correlation at some 
later stage. 
3.3 Conclusion 
 In conclusion, I synthesized highly functionalized novel 6H-benzo[c]chromenes by 
base mediated cyclocondensation of chloro substituted chromene-3-carbaldehydes with 
β-ketoesters and alkyl-3-oxo-pentanedioates. Owing to possess highly strained 
structures, the physical parameters of their molecular frameworks were discussed. 
UV/VIS and fluorescent measurements of some selected photo physically active 
compounds were carried out. A simplified justification for structure-fluorescence 
activity relationship was established. Biological assay studies of newly synthesized 
compounds are underway. 
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4. One-Pot synthesis of biaryl lactones by Sonogashira cross-coupling 
 reactions of 4-Chloro-3-formylcoumarin and subsequent domino 
 [5+1] cyclization/deacetylation reactions with 1, 3-dicarbonyl 
 compounds. 
4.1 Introduction 
 Sonogashira cross-coupling reaction is one of  the important class of Palladium 
catalyzed C-C bond formation processes which involve coupling of a terminal sp 
hybridized carbon from an alkyne with a sp2 carbon of an aryl or vinyl halide (or 
triflate) (Scheme. 13). The reaction was discovered in 1975 by Sonogashira, Tohda and 
Hagihara. The reaction is usually carried out at room temperature and under basic 
conditions using a palladium source such as PdCl2 (PPh3)2 with CuI as co-catalyst.
54 
R1 X-R2
cat. Pd(0)
Cu(I), Base
R1 R2
R1 = Aryl, Hetaryl, Alkyl, SiR3
R2 = Aryl, Hetaryl, Vinyl
X = I, Br, Cl, OTf  
Scheme 13.Typical Sonogashira reaction 
 A complete mechanism of Sonogashira reaction is not well understood mainly 
because of the involvement of two catalytic species, which are generally supposed to 
participate in two different but associated catalytic cycles A and B (Figure 13).55 
 Based on various mechanistic studies however a general compromise states that 
cycle A starts with an active Palladium specie Pd(0) that undergo an oxidative-addition 
with an Aryl, hetaryl or vinyl halide etc. The next step is transmetallation by 
copper(I)acetylide which is generated parallel during cycle B. Reductive elimination of 
the transmetallaed specie affords the coupled product and regenerates the Pd(0) 
catalyst.56 
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 The alkynylation of halogenated aryl systems and halogentated heterocycles under 
typical sonogashira cross-coupling conditions led to the synthesis of variety of natural 
products,57-64 bioactive molecules,65,66molecular electronics,67 conjugated 
polymers68and dendrimers69 etc. 
 
 
 
 
 
 
 
 
 
  
 
Figure 17. Supposed mechanism of copper co-catalyzed Sonogashira Reactions.56 
 In the group of Prof. Langer Sonogashira cross-coupling strategy have been 
successfully employed for the syntheses of Polyalkynylated Arenes and 
Polyalkynylated Heterocycles.70-76 Moreover within our group Ghazwan et al have 
adapted an advanced and efficient approach employing Sonogashira reactions for the 
synthesis of fused heterocyles.77Muller and co-workers reported the syntheses of 
variety of Heterocycles by consecutive multicomponent reactions initiated by 
Sonogashira cross-coupling reactions.77However despite these successful findings a 
step a head in Sonogashira chemistry is to use such reactions as a tool in 
benzoannulation of a heterocylic substratewas still a dream that needs to be fulfilled. 
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 Literature search revealed that Larock group has done comprehensive work on 
heterocyclic synthesesby using Sonogashira cross-coupling reactions and subsequent 
electrophilic and Palladium aided cyclizations.79Among these strategies Larock et al 
utilized halo-formyl substituted Arenes and heterocycles as their initial substrates. 
Sonogashira coupling reactions followed by imination with t-butyl amine afforded 
variety of isoquinoline and Carbolines derivatives.80With these positive literary 
findings; I decided to apply Palladium/Copper co-catalysis on my substrates of 
interests. 
4.2 Results and Discussion 
 The Sonogashira reactions of substrate 1 with aryl acetylenes and subsequent 
addition of 1, 3 dicarbonyl compounds afforded the biaryl lactones in one pot fashion 
(Scheme 14). 
 
  
 
 
 
  
 
 
Scheme 14. Reagents and Conditions: (i) 1 (1 mmol) 18a-i (1.5 mmol), 
PdCl2(PPh3)2 (4 mol %), CuI (7 mol %), THF 7-8 mL, K2CO3 (1.5 equiv.), 20 °C,  
                 8-10 hrs; (ii) 20a-f (1.5 mmol), 50 °C, 5-6 hrs. 
 In the first step I reacted substrate 1 with terminal alkynes 18a-i, the4-alkynyl-2-
oxo-2H-crhomene-3-carbaldehydes 19a-e intermediate species were formed which  
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Table 6.Synthesis of biaryl lactones 21a-x 
   18    20     21 R1 R2 Time (hrs) a Yield (%)b 
a a a 4-MeC6H4 CO2Me 8+5 48 
a b b 4-MeC6H4 CO2Et 8+5 47 
a c c 4-MeC6H4 COMe 8+5 43 
b c d Ph COMe 8+5 42 
b b e Ph CO2Et 8+5 46 
b a f Ph CO2Me 8+5 47 
b d g Ph CO2-iPr 8+5 44 
c d h nPr CO2-iPr 10+6 41 
c a i nPr CO2Me 10+6 38 
c b j nPr CO2Et 10+6 43 
c c k nPr COMe 10+6 41 
d c l nPent COMe 10+6 43 
d a m nPent CO2Me 10+6 45 
d b n nPent CO2Et 10+6 44 
e a o tBuC6H4 CO2Me 8+5 50 
e b p tBuC6H4 CO2Et 8+5 47 
e e q tBuC6H4 CO2-tBu 8+5 45 
e f r tBuC6H4 CO2-allyl 8+5 44 
f a s 2-MeC6H4 CO2Me 8+5 44 
g a t 4-nPr-C6H4 CO2Me 8+5 46 
h a u 4-FC6H4 CO2Me 8+5 54 
h b v 4-FC6H4 CO2Et 8+5 52 
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i a w 4-(MeO)C6H4 CO2Me 8+5 55 
i b x 4-(MeO)C6H4 CO2Et 8+5 54 
 
aThe first step involves room temp reaction for about 8 to 10 hrs. After addition of 1, 3-
dicarbonyl compounds the reaction mixture was heated to 50 °C for 5 to 6 hrs 
bYields of isolated products. 
were, without isolation, directly transformed to products 21 a-x by the addition of 1, 3-
dicarbonyl compounds 20a-f into the reaction mixture (Table 6). The formation of one 
of the intermediates 19a was proven by its isolation and characterization and then its 
subsequent transformation into corresponding product 21a.The structure of compound 
21f was confirmed by X-ray crystallographic analysis (Figure 18). 
 
Figure 18. Ortep plot of compound 21f 
 The best yields were obtained when PdCl2(PPh3)2 was used as the catalyst. The use 
of other catalyst such as Pd(PPh3)4 or Pd(OAc)2 were found to be less effective. The 
real problem i faced was the isolation of intermediate specie especially because of 
formation of soluble copper acetylide impurity got entangled with alkynl intermediate 
during column chromatography. Inspired by knoevenagel type deacetylation 
mechanism of previous successful work (see chapter. 2), I have decided to add directly 
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a 1, 3-dicarbonyl compound into the reaction vessel. On heating the reaction mixture a 
cyclization reaction leading to the formation of substituting ring C of biaryl lactone 
accomplished successfully. 
4.2.1 Proposed Mechanism  
The formation of the products can be explained by base-mediated attack of the 1, 3-
dicarobonyl compound on the aldehyde group in knoevenagel fashion to give 
intermediate A, which underwent further a base-mediated cyclization to give 
intermediate B, which subsequently converted to aromatized product by deactylation 
(Scheme 15). The overall process can be envisaged as a formal [5+1] cyclization. 1, 3-
dicaronyl compounds of type such as β-ketoesters and acetylacetone have shown 
successful reactions whereas both aryl and alkyl substituted alkynes were employed 
successfully. 
  
 
 
 
 
 
 
 
 
 
 
Scheme 15. Possible mechanism for the formation of compounds 21a-x 
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In the year 2011, a base-catalyzed cyclocondensations of methyl mercaptoacetate with 
heteroarenes, bearing a formyl and an alkynyl group located in a 1, 2-relationship, have 
been reported.81This reaction may also be presumed as a formal [5+1] cyclization, 
which proceeds by extrusion of H2S. Unfortunately, due to the mandatory use of 
methyl thioacetate, the preparative scope of the reaction is restricted. 
4.3 Conclusion 
 In conclusion, I have reported the one pot synthesis of biaryl lactones by 
Sonogashira cross-coupling reaction of 4-chloro-2-oxo-2H-chromene-3-carbaledehyde 
and subsequent cyclocondensation with 1, 3-dicarbonyl compounds. The cyclization 
proceeds by a novel domino [5+1] cyclization/deacytylation reaction. Though from a 
preparative viewpoint, the substitution pattern of the products is reported somewhere 
else. However from methodology viewpoint, the domino process reported has, to the 
best of our knowledge, not been reported so far and might be of general interest. The 
biological evaluation of synthesized products and the scope of reaction are under 
investigation. 
 
 
 
 
 
 
 
 
 
 
- 45 - 
 
5. Cyclocondensation reactions of electron rich heterocyclic enamines
 with heterocyclic chlorovinyl-aldehydes. Synthesis of novel 
heteroannulatedpyridines. 
5.1 Introduction 
Heteroannulated pyridines are known to possess anticipated pharmacological 
activities.82 Recently pyrrolo [2,3-b] pyridines derivatives are evaluatedas effective 
small molecular inhibitors of tumor necrosis factor alpha, P38 and Cdc7 Kinases. 
83,84,85One important synthetic route to achieve heteroannulated pyridines is the reaction 
of electorn rich enamines with carbonyl or Halo-carbonyl containing substrates. In the 
group of Prof. Langer an extensive work has been done on the reaction of electron rich 
enamines with bis-electrophilic substrates that afforded synthesis of novel 
benzochromones and benzochromenones heterocycles bearing an extended 
heteroannulated pyridine ring system. 
In one strategy 4-Chloro-3-(trifluoroacetyl)coumarin and 4-chloro-
3(methoxalyl)coumarins were treated with electron rich amino heterocycles to afford 
coumarin fused heteroannulated pyridines.86 In another approach 3-
methoxalylchromone was treated with heterocyclic enamines to give a set of 
heteroannulated pyridines bearing CO2Me functionality attached at the alpha position 
of pyridine ring.87Iaroshenko et al88 have synthesized functionalized heteroannulated 3-
nitropyridines by [3+3] cyclocondenation of 3-nitrochromone with electron-rich 
aminohetrocycles.88 In another methodology the reaction of heterocyclic enamines with 
3-acyl and 3-formyl indoles afforded heteroannulated pyridines. The transformation 
involved nucleophilic attack of aminoheterocycles on carbonyl functionality of indole 
that follows indole ring cleavage and subsequent cyclocondenstion to achieve a 
heteroannulated pyridine ring system in a less common domino style reaction.89A 
general schematic overview of such reactions is given in figure 19. 
One important field in the modern drug design is the synthesis of DNA-
intercalating agents. These agents bind to DNA via intercalation and exert their action 
through Topoisomerase II inhibition, an enzyme responsible to control changes in 
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DNA replication and transcription. Such compounds more or less share common 
structural characteristics, such as having poly aromatic planar rings, overall linear 
molecular skeleton and presence of heterocyclic core.90 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19. Synthesis of heteroannulated pyridines based on electron rich amino 
     heterochycles 
Heterocyclic electron rich enamines bear two different nucleophilic sites. Due 
to this peculiar nature, their cyclocondenstion reactions with bis-electrophilic 
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substrates like heterocyclic chlolrovinyl-aledehydes may result two different 
regiomeric products, which have different forms either linear or non-linear relative to 
each other (Figure 20). 
NCl
H
O
Het. Het.Het.
N
Het
Het.
Linear Non-linear
NH2
Het
H2N
Het.
 
Figure 20. Regiomeric outcome of reactions of electron rich enamines with  
 heterocyclic chlorovinyl-aldehydes 
While working on the chemistry of Halo-carbonyl containing compounds 
laroshenko and co-workers, when treated a heterocyclic chlorovinyl-aldehyde (4-
chloro-2-oxo-2H-chromene-3-carbaldehyde) (1) with a heterocyclic enamine (5-amino-
1-tert-butyl-1H-pyrrole-3-carbonitrile) (22a), they got regioselectively pure non-linear 
tetracyclic compound 23a in 40% yield86(Scheme 16). 
NH2N
CN
O O
Cl
H
O
i
O O
N
N
1 22a 23a
O O
N
23b (not observed)
NC
N
CN
 
Scheme 16.Synthesis of 23a.Reagents and Conditions: (i), 1 (2 mmol) 22 (2  
   mmol),TMSCl 1mL, DMF 10 mL, 100-120 °C, 2-10 hrs. 
The researchers did not claim to observe the formation of linear regiomer 23b 
under given set of reaction conditions. However in another similar study they observed 
a completely different regiochemistry. When they treated4-chloro-3-(2, 2, 2-
trifluoroacetyl-2H-chromen-2-one (24) with electron rich enamine (3-mehtyl-1-phenyl-
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1H-pyrazol-5-amine) (25), interestingly they got a linear tetracyclic compound 26a 
instead of its expected non-linear counterpart 26b.86 (Scheme 17). 
O O
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H2N
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O O
N
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O O
N
NN
24 25
26a 26b
(not observed)
CF3 CF3
          
     Scheme 17. Synthesis of 26a.Reagents and Conditions: (i), 1 (2 mmol) 22 (2    
               mmol),TMSCl 1mL, DMF 10 mL, 100-120 °C, 2-10 hrs. 
The successful appearance of such linear tetracyclic compound inspired me to 
extend the chemistry of electron rich enamines towards chlorovinyl-aldehydes 
substrates of interests and enlightened my hope to look for tetracyclic heterocyclic 
compounds with linear configuration relative to their non-linear regiomeric analogues. 
5.2 Result and Discussions 
In order to look for the possibility of formation of compound 23b, I repeated 
the procedure of Iaroshenko et al.86and got same results, however i found purification 
of product 23a bit difficult because of highly polar nature of DMF and its high boiling 
point. I carried out the reaction using AlCl3 and MeOH; the conditions successfully 
applied previously for the synthesis of variety of heteroannulated pyridines. 89I again 
observed compound 23a as major component formed, however I noticed the formation 
of two more compounds as indicated by TLC, I tried to separate the components but 
unfortunately could not do so. I changed my strategy and set another reaction of 
substrate 1 with 3-mehtyl-1-phenyl-1H-pyrazol-5-amine (25) under similar reaction 
conditions. Fortunately, I got the desired linear tetracyclic product 27a in 58% yield 
(Scheme 18). Indeed, the formation of regiomer 27b was also observed as indicated by 
the GC spectra of reaction mixture, which gave two similar molecular ion peaks. 
Momentarily, taking it out of the scope of current subject, the isolation of regiomer 27b 
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was not proceeded further. The structure of linear tetracyclic compound 27a was 
confirmed using 1D and 2D NMR techniques. 
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1 25
27a 27b
(not isolated)  
Scheme 18. Syntheis of 27a. Reagents and conditions (i), 1 (1 mmol), 25 (1.2    
          mmol), AlCl3 (3.0 equiv.), MeOH 10 ml, Reflux 8 - 10 hrs. 
Working on the same line when i treated 4-chloro-2H-chromene-3-carbaldehyde 
(2) with 5-amino-1-tert-butyl-1H-pyrrole-3-carbonitrile (22a) in the presence of 
TMSCl and DMF, unexpectedly, I got a schiff base 28a as the only product in a very 
good yield. 
 
 
 
 
 
 
 
 
Scheme 19. Reagents and Conditions: (i) 2 (1 mmol) 22a (1.2 mmol), TMSCl         
1mL, DMF 10 mL, 100-120 ̊C, 2-10 hrs. (ii) 2 (1mmol) 22a-c (1.2 mmol), AlCl3 
(3.0 equiv.), MeOH 10 mL, Reflux 8-10 hrs. 
O
Cl
H
O
N
NH2
R
CN O
Cl
H
N
O
H
N
N
R
CN
N
R
NC
29a-c
i
2
28a
ii
R = t Butyl, 4-Methoxybenzyl,
      cyclohexyl.
22a-c
- 50 - 
 
However when the reactions was carried out in AlCl3/MeOH, i got desired cyclic 
products 29a-c in affordable yields. A completely different behavior of reaction of 4-
chloro-2H-chromene-3-carbaldehyde (2) and N-substituted α-amino pyrroles under two 
different set of conditions is shown in (Scheme 19) (Table 7). 
 Table7. Synthesis of 29a-c 
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        ayields of isolated product.  
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The crystalline nature of schiff base allows me to grow crystals in appropriate solvents. 
The Ortep plot of schiff base 28a is given in figure 21. 
 
Figure21. Ortep Plot of compound 28a 
  Fortunately, reaction of 4-chloro-2H-chromene-3-carbaldehyde (2) with 3-
methyl-1-phenyl-1H-pyrazol-5-amine (25) afforded  linear heteroannulated 
compound 30 in 58% yield (Scheme 20). 
O
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N
H2N
i
O
N
NN
2 25 30
 
 Scheme 20. Syntheis of 30. Reagents and conditions (i), 2 (1 mmol), 25 (1.2    
            mmol), AlCl3 (3.0 equiv.), MeOH 10 ml, Reflux 8-10 hrs. 
Inorder to extend the scope of synthesis, I chose to apply the strategy to 4-
chloroquinoline-3-carbaldehyde (4) a heterocyclic chloroviny-aldehyde substrate 
analogous to substrate 2. Unexpectedly, no reaction of substrate 4 with any 
heterocyclic enamine was observed in TMSCl and DMF, whereas very poor yields 
were obtained in case of AlCl3 in MeOH reactions conditions. Iaroshenko and co-
workers have successfully used glacial acetic acid as solvent and catalyst for the 
reaction between some selected aminoheterocylces and formylindoles.89Luckily, when 
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i used glacial CH3COOH as solvent, I got the required annulated pyridines with desired 
regioselectivity (Scheme 21). 
N
Cl
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N
R
CN
NH2
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N
N
R
CN
i
4 22a,b
31a, 33 %; 31b, 52 %
R = t butyl,  4-methoxy benzyl  
 Scheme 21. Reagents and Conditions: (i) 4 (1mmol), 22a,b (1.2 mmol) glacial  
    CH3COOH 10 ml, Reflux 8-10 hrs. 
 The structure of compound 30 and 31b was confirmed by X-ray crystallographic 
analysis (Figure 22 and 23). 
 
Figure22. The Ortep plot of 30 
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Figure.23 The Ortep plot of 31b 
 Fruitfully, under similar reaction conditions, when i treated substrate 4 with 3-
methyl-1-phenyl-1H-pyrazol-5-amine (25), i got a tetracyclic heteroannulated pyridine 
32 in 57% yield (Scheme 22).  
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4 25 32, 57 %
 
       Scheme 22. Reagents and Conditions: (i) 4 (1mmol), 25 (1.2 mmol) Glacial  
      CH3COOH 10 ml, Reflux 8-10 hrs. 
5.2.1 Proposed Mechanism 
Nevertheless, two different set of reaction conditions came up with successful 
condensation results. By taking into consideration acid surroundings in all the cases, a 
common mechanism could be postulated involving protonic specie used to activate the 
chloro-formyl substrate for nucleophilic attack, which is available directly, if acetic 
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acid is used as solvent or come through Lewis acid-solvent interaction in case of 
AlCl3in MeOH.
91 However, depending on the binucleophilic nature of heterocyclic 
enamines, two cyclic modes A & B of the mechanism may be hypothesized for the 
synthesis of tetracyclic annulated pyridines 29-32 (Figure 19).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24. Plausible mechanism for the formation of heteroannulated pyridines. 
Cycle A is assumed to proceed by nucleophilic attack of amino group of 
enamines 22 or 25 on the activated chloro group of substrates 1, 3, 4 leading to 
intermediate I, which underwent intramolecular cyclization via attack of C-4 
nuculeophilic site on activated electrophilic carbonyl centre to afford annulated 
pyrdinium ion III, which on proton removal gave aromatized tetracyclic 
heteroannulated pyridine product. Cycle B started with the nucleophilic attack of C-4 
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of enamines 22 or 25 to carbonyl group of heterocyclic chloroviny-aldehydes 
substrates 1, 3, 4 leading to an iminium intermediate II, which is thought to undergo a 
pericyclic type rearrangement with concomitant removal of HCl to give pyridinium 
adduct III, which underwent aromatization after deprotonation affording  desired linear 
heteroannulated pyridine compounds 29-32. 
Unfortunately I could not isolate the intermediate compounds I and II. However 
formation of schiff base 28a as only product during the reaction of 4-chloro-2H-
chromene-3-carbaldehyde (2) with5-amino-1-tert-butyl-1H-pyrrole-3-carbonitrile 22a 
and the observation of schiff bases contaminations by TLC and GC-MS data for 
annulations reactions leading to cyclized products led me to conclusion that most 
probably, the linear tetracyclic annulated pyridines follows path A, whereas nonlinear 
or curved shape annulated pyridine compounds were formed by attack of amino group 
to carbonyl functionality leading to schiff base formation, which finally underwent 
cycloaromatization by  the attack of C-4 of enamine to chloro group resulting non-
linear heteroannulated pyridines. Based on these observations it is suggested that in 
literature the mechanistic postulation for the synthesis of non-linear heteroannulated 
pyridines via attack of C-4 site of enamine to chloro group first could be revised and 
reevaluated. 
5.3 Conclusion 
 In conclusion, I have reported synthesis of novel heteroannulated pyridines of 
pharmacological interests. Different reaction conditions were used successfully for the 
reactions of heterocyclic enamines such as 2-aminopyrrole and 2-aminopyrazole with 
heterocyclic chlorovinyl-aldedhydes substrates to afford novel tetracyclic linear 
annulated pyridines. Anticancer evaluation of these heterocyclic compounds is under 
process. Moreover, we are in preparation to extend further the scope towards the 
reaction of variety of heterocyclic enamines with different bi-electrophilic substrates. 
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6  Experimental Section 
6.1  Technique and Equipment 
6.1.1 1H NMR Spectroscopy: Bruker AM 250, Bruker ARX 300; δ = 0.00 ppm 
  for Tetramethylsilane; δ = 7.26 ppm for (CDCl3); Characterization of the  
  signals: s = singlet, d = doublet, dd = doublet of doublets, t = triplet, q =  
  quintet; sext = sextet, sept = septet, dt = doublets of triplet; td = triplets of  
  doublet etc. All coupling constants are indicated as (J). 
6.1.2 13C NMR Spectroscopy: Bruker AM 250, (62.9 MHz); Bruker: ARX 300, 
  (75 MHz); Ref: = 77.00 ppm for CDCl3. The multiplicity of the carbon  
  atoms was determined by the DEPT 135 and quoted as CH3, CH2, CH and  
  C for primary, secondary, tertiary and quaternary carbon atoms,   
  respectively. 
6.1.3 Mass Spectrometry: AMD MS40, AMD 402 (AMD Intectra), Varian  
  MAT CH 731. High Resolution mass spectroscopy: Finnigan MAT 95 or  
  Varian MAT 311; Bruker FT CIR, AMD 402 (AMD Intecta). 
6.1.4 Infrared Spectrscopy (IR): Bruker IFS 66 (FT IR), Nicolet FT IR; Nicolet 
  Protégé 460, Nicolet 360 Smart rbit (ATR); KBr, KAP, Nujol, and ATR;  
  Abbreviations for signal allocations: w = weak, m = medium, s = strong, br 
  = broad. 
6.1.5 Elementary analysis: LECO CHNS-932, Thermoquest Flash EA 1112. 
6.1.6 X-ray crystal structure analysis: Bruker X8Apex Diffractometer with  
  CCD-Kamera (Mo-Kα and graphite monochromator, λ = 0.71073 Å). 
6.1.7 Melting point: Micro heating table HMK 67/1825 Kuestner (Buchi-app.). 
  Melting points are uncorrected. 
6.1.8 Column chromatography: Chromatography was performed over Merck  
  silica gel 60 (0.063-0.200 mm, 70-230 mesh) as normal and/ or over silica  
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  gel 60 (0.040-0.063 mm, 200-400 mesh) as flash chromatography. All  
  solvents were distilled before use. 
6.1.9 Thin layer chromatography: Merck DC finished aluminum foils silica gel 
  60 F254 and Macherey finished foils Alugram® Sil G/UV 254. Detection  
  under UV light at 254 nm and/or 366 nm without dipping reagent, as well  
  as with locating agent vanillin-sulfuric acid reagent (1 mL vanillin in 100  
  mL stock solution of 85% methanol, 14% acetic acid and 1% sulfuric acid). 
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6.2   Synthetic Procedures  
6.2.1General Procedure for the synthesis of compounds 9a-l 
 To a solution of 4-chloro-2-oxo-2H-chromene-3-carbaldehyde (1) (100 mg, 0.5 
mmol) in THF (10 mL) was added K2CO3 (140 mg, 2.0 equiv.). To the stirred solution 
β-ketoester 8 (1mmol, 2.0 equiv.) was added dropwise. The reaction mixture was 
allowed to stir at 50 °C and monitored by TLC. After the complete consumption of the 
starting material 1, the reaction mixture was acidified using few drops of HCl (1M) and 
extracted with ethyl acetate. The combined organic layers were dried with Na2SO4 and 
solvent was removed under reduced pressure. The residues were purified by column 
chromatography (silica gel, n-heptane/EtOAc = 3:2). 
6.2.2General Procedure for the synthesis of compounds 11a and 11b 
 To a solution of 4-chloro-2-oxo-2H-chromene-3-carbaldehyde (1) (0.5 mmol) in 
THF (10 mL) was added K2CO3 (140 mg, 2.0 equiv.). To the stirred solutiondialkyl-3-
oxopentanedioate (10) (1 mmol, 2.0 equiv.) was added dropwise. The reaction mixture 
was allowed to stir at 50 °C and was monitored by TLC. After the complete 
consumption of the starting material 1, the reaction mixture was acidified using few 
drops of HCl (1M) and extracted with ethyl acetate. The combined organic layers were 
dried with Na2SO4 and solvent was removed under reduced pressure. The residues 
were purified by column chromatography (silica gel, n-heptane/EtOAc=3:2). 
6.2.3 General Procedure for the synthesis of compound14a-c, e, m 
 To a solution of 4-chloro-2H-chromene-3-carbaldehyde (2) (1 mmol) in DMF (10 
mL) was added Cs2CO3 (650 mg, 2.0 equiv.). To the stirred solution was drop wise 
added the corresponding β-ketoester (2 mmol, 2.0 equiv.). The reaction mixture was 
allowed to stir at 50 °C and monitored by TLC. After the complete consumption of the 
starting material 2, the reaction mixture was acidified using few drops of HCl (1M) and 
was extracted with ethyl acetate. The combined organic layers were dried with Na2SO4 
and solvent was removed under reduced pressure. The residues were purified by 
column chromatography (silica gel, n-heptane/EtOAc = 4:1). 
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6.2.4 General Procedure for the synthesis of compound 16a-c 
 To a solution of 4-chloro-2H-chromene-3-carbaldehyde (2) (1 mmol) in THF (10 
mL) was added K2CO3 (140 mg, 2.0 equiv.). To the stirred solutiondialkyl-3-
oxopentanedioates (10) (2 mmol, 1.2 equiv.) was added dropwise. The reaction mixture 
was allowed to stir at 50 °C and was monitored by TLC. After the complete 
consumption of the starting material2, the reaction mixture was acidified using HCl 
(1M) and extracted with ethyl acetate. The combined organic layers were dried with 
Na2SO4 and solvent was removed under reduced pressure. The residues were purified 
by column chromatography (silica gel, n-heptane/EtOAc = 3:2). 
6.2.5 General Procedure for the synthesis of compound 17a-c 
 To a solution of 4-Chloro-2-phenyl-2H-chromene-3-carbaldehyde (3) (1 mmol) in 
DMF (10 mL) was added K2CO3 (140 mg, 2.0 equiv.). To the stirred solutiondialkyl-3-
oxopentanedioate (10) (2 mmol, 1.0 equiv.) was added dropwise. The reaction mixture 
was allowed to stir at 50 °C and monitored by TLC. After the complete consumption of 
the starting material 3, the reaction mixture was acidified using HCl (1M) and extracted 
with ethyl acetate. The combined organic layers were dried with Na2SO4 and solvent 
was removed under reduced pressure. The residue was purified by column 
chromatography (silica gel, n-heptane/EtOAc = 3:2). 
6.2.6 General Procedure for the synthesis of compound 21a-x 
 To a solution of 1 (1.0 mmol) in THF (7-8 mL) were added K2CO3 (180 mg, 1.5 
equiv.). Under continuous supply of Argon was added PdCl2(PPh3)2 (4 mol %) and CuI 
(7 mol %) followed by drop wise addition (after an interval of 2-5 min) of substituted 
terminal acetylene 18 (1.5 equiv.). The reaction mixture was allowed to stir at room 
temperature for 8 to 10 h and monitored by TLC. To the same reaction vessel was 
dropwise added the 1, 3-dicarbonyl compound 20 (1.5 equiv.). The reaction was then 
stirred at 50 °C for 5 to 6 h. After completion of reaction, the reaction mixture was 
acidified by addition of a few drops of hydrochloric acid (1 M). The mixture was then 
extracted with ethyl acetate. The solvent was removed under reduced pressure. The 
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residue was purified by column chromatography (silica gel, n-heptane/EtOAc = 3:2 and 
4:1). 
6.2.7 General Procedure for the synthesis of compound 29a-c and 30 
 4-Chloro-2H-chromene-3-carbaldehyde (2) (1 mmol) was treated with each 
ofheterocyclic enamines 22 and 25 (1.2 mmol) in 10-15 mL of dry MeOH in separate 
reactions. To each reaction mixture anhydrous AlCl3 (3 equiv.) was added. The reaction 
mixture was refluxed under moisture free environment for 8-10 hrs. The solid residue 
formed was filtered and washed with cold MeOH. The solid was again dissolved in hot 
MeOH and filtered. The two filtrates obtained were combined, adsorbed on silica gel 
and purified by chromatography using two solvent systems (silica gel, n-
heptane/EtOAc = 3:2, chloroform/n-heptane = 9:1). 
6.2.8 General Procedure for the synthesis of compound 31a, b and 32 
4-Chloroquinoline-3-carbaldehyde (4) (1 mmol) was treated with each ofheterocyclic 
enamines 22 and 25 (1.2 mmol) in 10-15 mL glacial acetic acid in separate reactions. 
The reaction mixtures were allowed to reflux for 10 hrs under moisture free 
environment. The reaction mixtures were allowed to cool. Acetic acid was evaporated 
under vacuum. The dried residues were treated with 10 % Na2CO3solution and 
subjected to solvent extraction with ethyl acetate. The ethyl acetate extracts were dried 
with Na2SO4, adsorbed on silica gel and purified by chromatography (silica gel, n-
heptane/EtOAc = 3:2) to give white crystalline solid. 
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7.   Spectroscopic data 
Dimethyl 9-methyl-6-oxo-6H-benzo[c]chromene-8,10-dicarboxylate (9a): Starting 
with 1 (100mg, 0.5 mmol) and 8a (120 mg, 1.0 mmol), 9a (120 
mg, 75%) was isolated as white crystalline solid, m.p. 173-175 
°C. 1H NMR (300 MHz, CDCl3): δ = 2.58 (s, 3H, CH3), 3.88 (s, 
3H, OCH3), 3.9 (s, 3H, OCH3), 7.17-7.23 (m, 1H, ArH), 7.31(dd, 
J = 8.28 Hz, J = 1.29 Hz, 1H, ArH), 7.42-7.48 (m, 1H, ArH), 
7.70 (dd, J = 8.31 Hz, J = 1.29 Hz, 1H, ArH), 8.89 (s, 1H, ArH). 13C NMR (250 MHz, 
CDCl3): δ = 18.1 (CH3), 52.5, 53.1 (OCH3), 116.1 (C), 118.4 (CH), 119.9 (C), 124.7, 
124.7 (CH), 131.1 (C), 131.7 (CH), 131.7, 133.5 (C), 133.8 (CH), 144.0, 151.8 (C), 
159.9, 166.0, 170.0 (CO). IR (ATR, cm-1): ν = 2949 (w), 1716 (s), 1599(m), 1429 (m), 
1115 (m), 1194 (s), 1292 (w) 1041 (m), 971 (m), 748 (s), 640 (m). GC-MS (EI, 70 eV): 
m/z (%) = 326 ([M]+, 100), 295 (77), 266 (19), 237 (16), 208 (4). HRMS (EI): calcd. 
for C18H14O6 ([M]
+): 326.07849.Found: 326.07846. Anal.calc. for C18H14O6: C, 66.26; 
H, 4.32. Found: C, 66.48; H, 4.73. 
Diisopropyl 9-methyl-6-oxo-6H-benzo[c]chromene-8,10-dicarboxylate (9b): Starting 
with 1 (100 mg, 0.5 mmol) and 8b (140 mg, 1.0 mmol), 9b 
(137 mg, 72%) was isolated as white crystalline solid,m.p. 
122-124°C. 1H NMR (300 MHz, CDCl3): δ = 1.33 (d, J = 6.27 
Hz, 6H, 2CH3), 1.34 (d, J = 6.27 Hz, 6H, 2CH3), 2.60 (s, 3H, 
CH3), 5.22 (sp, J = 6.27 Hz, 1H, OCH), 5.40 (sp, J = 6.27 Hz, 1H, OCH), 7.17-7.23 
(m, 1H, ArH), 7.32(dd, J = 8.31 Hz, J = 1.29 Hz, 1H, ArH), 7.43-7.49(m, 1H, ArH), 
7.91 (dd, J = 8.31 Hz, J = 1.29 Hz, 1H, ArH), 8.82 (s, 1H, ArH). 13C NMR (300 MHz, 
CDCl3): δ = 17.9 (CH3), 21.5, 21.7 (2CH3), 69.5, 70.4 (OCH), 116.39(C), 118.3 (CH), 
119.9 (C), 124,3, 125.3, 131.6 (CH), 132.4, 132.4, 132.9 (C), 133.1 (CH), 143.4, 
151.7(C), 160.1, 166.6, 169.1 (CO). IR (ATR, cm-1): ν = 2982 (w), 2932 (w), 1739 (s), 
1718 (s), 1702 (s), 1603 (m), 1459 (m), 1293 (w), 1223 (s), 1194 (s), 1100 (s), 
1039(m), 907 (m), 752 (s), 636 (m). GC-MS (EI, 70 eV): m/z (%) = 382 ([M]+, 34), 
323 (36), 298 (100), 297 (89), 281 (30), 252 (15). HRMS (EI): calcd. for C22H22O6 
([M]+): 382.14109.Found: 382.14092. Anal.calc. for C22H22O6: C, 69.10; H, 5.80. 
Found: C, 69.26; H, 5.99. 
O O
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O
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Diethyl 9-methyl-6-oxo-6H-benzo[c]chromene-8,10-dicarboxylate (9c): Starting with 
1 (100 mg, 0.5 mmol) and 8c (130 mg, 1.0 mmol), 9c (128 
mg, 71%) was isolated as white crystalline solid, m.p. 121-
123 °C. 1H NMR (300 MHz, CDCl3): δ = 1.32-1.38 (m, 6H, 
2CH3), 2.60 (s, 3H, CH3), 4.33 (q, J = 7.14 Hz, 2H, OCH2), 
4.46 (q, J = 7.14 Hz, 2H, OCH2), 7.17-7.23 (m, 1H, ArH), 7.32 (dd, J = 8.10 Hz, J = 
1.2 Hz, 1H, ArH), 7.43-7.48(m, 1H, ArH), 7.81 (dd, J = 8.4 Hz, J = 1.5 Hz, 1H, ArH), 
8.87 (s, 1H, ArH). 13C NMR (300 MHz, CDCl3): δ = 13.8, 14.2, 18.1 (CH3), 61.7, 62.5 
(OCH2), 116.3 (C), 118.4 (CH), 119.9 (C), 124.5, 125.0, 131.6 (CH), 131.7 (C), 132.1, 
133.3 (C), 133.4 (CH), 143.8, 151.8 (C), 160.0, 165.8, 169.6 (CO). IR (ATR, cm-1): ν = 
2982 (w), 1712 (s), 1600(m), 1435 (m), 1293 (m), 1091 (s), 749 (s), 640 (m). GC-MS 
(EI, 70 eV): m/z (%) = 354 ([M]+, 100), 309 (72), 297 (57), 281 (34), 252 (18), 152 
(16). HRMS (EI): calcd. for C20H18O6 ([M]
+): 354.10979. Found: 354.11034.  
Bis(2-methoxyethyl)9-methyl-6-oxo-6H-benzo[c]chromene-8,10-dicarboxylate (9d): 
Starting with 1 (100 mg, 0.5 mmol) and 8d (160 
mg, 1.0 mmol), 9d (120 mg, 60%) was isolated as 
off-white solid, m.p. 78-80 °C. 1H NMR (300 MHz, 
CDCl3): δ =  2.59 (s, 3H, CH3), 3.27(s, 3H, OCH3), 
3.35 (s, 3H, OCH3), 3.62-3.68 (m, 4H, 2OCH2), 
4.41-4.44 (m, 2H, OCH2), 4.54-4.57 (m, 2H, OCH2), 7.15-7.21 (m, 1H, ArH), 7.29 (dd, 
J = 8.28 Hz, J = 1.29 Hz, 1H, ArH), 7.41-7.46 (m, 1H, ArH), 7.83 (dd, J = 8.28 Hz, J = 
1.26 Hz, 1H, ArH), 8.87 (s, 1H, ArH). 13C NMR (300 MHz, CDCl3): δ = 18.0 (CH3), 
58.9, 59.0 (OCH3), 64.6, 65.0, 69.8, 70.2 (OCH2), 116.2 (C), 118.3 (CH), 119.9 (C), 
124.6, 125.2 (CH), 131.4 (C), 131.7 (CH), 131.8, 133.5 (C), 133.6 (CH), 143.9, 
151.8(C), 159.9, 165.8, 169.5 (CO). IR (ATR, cm-1): ν = 2925 (w), 2880 (w), 2842 (w), 
2820 (w), 1711 (s), 1602 (m), 1434 (m), 1213 (s), 1188 (s), 1120 (s), 1046 (m), 752 (s), 
642 (m). GC-MS (EI, 70 eV): m/z (%) = 414 ([M]+, 37), 339 (100), 298 (50), 252 (36), 
152 (19). HRMS (EI): calcd. for C22H22O8 ([M]
+): 414.13092. Found: 414.13143.  
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Diallyl 9-methyl-6-oxo-6H-benzo[c]chromene-8,10-dicarboxylate (9e): Starting with 
1 (100 mg, 0.5 mmol) and 8e (140 mg, 1.0 mmol), 9e 
(145 mg, 60%) was isolated as white crystalline 
solid,m.p. 112-113 °C. 1H NMR (250 MHz, CDCl3): 
δ = 2.60 (s, 3H, CH3), 4.78 (dt, J = 5.89 Hz, 1.26 Hz, 
2H, CH2), 4.89 (dt, J = 6.20 Hz, 1.12 Hz, 2H, CH2), 
5.24-5.43 (m, 4H, 2OCH2), 5.87-6.06 (m, 2H, 2CH), 7.15-7.22 (m, 1H, ArH), 7.32 (dd, 
J = 8.23, 1.46 Hz, 1H, ArH), 7.43-7.49 (m, 1H, ArH), 7.81 (dd, 8.32 Hz, 1.30 Hz, 1H, 
ArH), 8.91 (s, 1H, ArH). 13C NMR (250 MHz, CDCl3): δ = 18.1 (CH3), 66.3, 67.0 
(OCH2), 116.1 (C), 118.3 (CH), 119.3 (CH2), 119.9 (C), 120.8 (CH2), 124.6, 125.2, 
130.4 (CH), 131.3 (C), 131.5, 131.7 (CH), 131.8, 133.5 (C), 133.7 (CH), 144.0, 
151.8(C), 159.9, 165.3, 169.2 (CO). IR (ATR, cm-1): ν = 3086 (w), 2959 (w), 1721 (s), 
1714 (s), 1598 (m), 1434 (m), 1290 (m), 1217 (s), 1185 (s), 1119 (m), 1037 (m), 939 
(m), 753 (s).GC-MS (EI, 70 eV): m/z (%) = 378 ([M]+, 94), 337 (28), 321 (100), 309 
(64), 293 (47), 275 (18), 237 (23). HRMS (ESI-TOF/MS): calcd. for C22H19O6 
([M+H]+): 379.11761. Found: 379.11721. 
Dibenzyl 9-methyl-6-oxo-6H-benzo[c]chromene-8,10-dicarboxylate (9f): Starting 
with 1 (100 mg, 0.5 mmol) and 8f (192 mg, 1.0 
mmol), 9f (148 mg, 62%) was isolated as white 
crystalline solid m.p. 142-144 °C. 1H NMR (250 
MHz, CDCl3): δ = 2.53 (s, 3H, CH3), 5.31 (s, 
2H, OCH2), 5.41 (s, 2H, OCH2), 6.83-6.90 (m, 1H, ArH), 7.25-7.41(m, 12H, ArH), 
7.60 (dd, J = 8.35 Hz, 1.32 Hz, 1H, ArH), 8.89 (s, 1H, ArH). 13C NMR (250 MHz, 
CDCl3): δ = 18.1 (CH3), 67.4, 68.3 (OCH2), 116.0 (C), 118.2 (CH), 119.9 (C), 124.4, 
125.1 (CH), 128.4 (2CH), 128.5 (CH), 128.7 (2CH), 128.8 (2CH), 129.0 (CH), 129.5 
(2CH), 131.3 (C), 131.6 (CH), 131.8, 133.5 (C), 133.6 (CH), 133.9, 135.3, 144.0 
151.7(C),159.9, 165.5, 169.2 (CO). IR (ATR, cm-1): ν = 3033 (w), 2966 (w), 1733 (s), 
1712 (s), 1598(m), 1555 (w), 1454 (w), 1211 (s), 1189 (s), 1120 (m), 1031 (s), 1120 
(m), 948 (m), 745 (s), 697 (s). GC-MS (EI, 70 eV): m/z (%) = 478 ([M] +, 72), 387 
(70), 371 (43), 369 (17), 344 (15), 281 (10), 91 (100), 65 (12). HRMS (EI): calcd. for 
C30H22O6 ([M]
+): 478.14109. Found: 478.14154.  
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Dimethyl 9-ethyl-6-oxo-6H-benzo[c]chromene-8,10-dicarboxylate (9g): Starting with 
1 (100 mg, 0.5 mmol) and 8g (130 mg, 1.0 mmol), 9g (77 mg, 
45%) was isolated as white crystalline solid, m.p. 174-176 °C. 
1H NMR (300 MHz, CDCl3): δ = 1.22 (t, J = 7.48 Hz, 3H, CH3), 
2.98 (q, J = 7.41 Hz, 2H, CH2), 3.89 (s, 3H, OCH3), 3.95 (s, 3H, 
OCH3), 7.19-7.21 (m, 1H, ArH), 7.32 (dd, J = 8.22 Hz, J = 1.17 
Hz, 1H, ArH), 7.43-7.49(m, 1H, ArH), 7.74 (dd, J = 8.31 Hz, J = 1.23 Hz, 1H, ArH), 
8.91 (s, 1H, ArH). 13C NMR (300 MHz, CDCl3): δ = 14.8 (CH3), 24.1 (CH2), 51.5, 
51.9, (OCH3), 115.3 (C), 117.4 (CH), 119.0 (C), 123.6, 123.8 (CH), 129.7 130.3 (C), 
130.7 (CH), 132.8 (C), 133.3 (CH), 148.9 150.8(C),158.9, 164.9, 168.88(CO). IR 
(ATR, cm-1): ν = 2954 (w), 1716 (s), 1598(m), 1431 (m), 1255 (m), 1216 (s), 987(m), 
760 (s) 735 (s), 626 (m). GC-MS (EI, 70 eV): m/z (%) = 340 ([M]+, 61), 325 (100),309 
(36), 293 (31), 280 (16), 249 (13). HRMS (EI): calcd. for C19H16O6 ([M]
+): 340.09414. 
Found: 340.09433.  
Dimethyl 9-(chloromethyl)-6-oxo-6H-benzo[c]chromene-8,10-dicarboxylate (9h): 
Starting with 1 (100 mg, 0.5 mmol) and 8h (150 mg, 1.0 
mmol), 9h (130 mg, 72%) was isolated as light orange solid, 
m.p. 222-224 °C. 1H NMR (300 MHz, CDCl3): δ = 3.89(s, 3H, 
OCH3), 3.96 (s, 3H, OCH3), 5.11 (s, 2H, CH2Cl), 7.21-7.27 (m, 
1H, ArH), 7.34 (dd, J = 8.10 Hz, J = 1.20 Hz, 1H, ArH), 7.47-
7.528 (m, 1H, ArH), 7.70 (dd, J = 8.10 Hz, J = 1.20 Hz, 1H, ArH), 8.99 (s, 1H, ArH). 
13C NMR (300 MHz, CDCl3): δ = 38.2 (CH2), 53.0, 53.3 (OCH3), 116.0 (C), 118.5 
(CH), 122.1 (C), 124.8, 125.0 (CH), 130.3, 131.9 (C), 132.2, 134.7 (CH), 142.1, 
151.9(C), 159.4, 165.3, 168.9 (CO). IR (ATR, cm-1): ν = 2951 (w), 2922 (w), 1716 (s), 
1598(m), 1438 (m), 1234 (s), 1120 (m), 1009 (m), 929 (m), 740 (s), 693 (m). GC-MS 
(EI, 70 eV): m/z (%) = 360 ([M]+, 46), 309 (100), 324 (33), 293 (11), 266 (19). HRMS 
(EI): calcd. for C18H13O6Cl ([M]
+): 360.03952. Found: 360.03985.  
 
 
O O
OO
OO
O O
OO
OO
Cl
- 65 - 
 
Diethyl 9-(chloromethyl)-6-oxo-6H-benzo[c]chromene-8,10-dicarboxylate (9i): 
Starting with 1 (100 mg, 0.5 mmol) and 8i (160 mg, 1.0 
mmol), 9i (139 mg, 73%) was isolated as light yellow 
flakes, m.p. 108-109 °C. 1H NMR (300 MHz, CDCl3): δ = 
1.32 (t, J = 7.17 Hz, 3H, CH3), 1.39 (t, J = 7.17 Hz, 3H, 
CH3), 4.37-4.51 (m, 4H, 2CH2), 5.11 (s, 2H, CH2Cl), 7.20-
7.25 (m, 1H, ArH), 7.34 (dd, 8.32 Hz, 1.32 Hz, 1H, ArH), 7.46-7.52 (m, 1H, ArH), 
7.79 (dd, 8.27 Hz, 1.30 Hz, 1H, ArH), 8.96 (s, 1H, ArH). 13C NMR (250 MHz, CDCl3): 
12.7, 13.1 (CH3), 37.3 (CH2), 61.3, 62.0 (OCH2), 115.0 (C), 117.4 (CH), 121.1 (C), 
123.6, 124.2, 129.8 (CH), 131, 131 (C), 133.4 (CH), 140.8, 150.8(C), 158.4, 163.9, 
167.5 (CO). IR (ATR, cm-1): ν = 2974 (w), 2934 (w), 1716 (s), 1600 (m), 1461 (m), 
1439 (m), 1298 (m), 1230 (s), 1195 (m), 1013 (s), 743 (s). GC-MS (EI, 70 eV): m/z 
(%) = 295 ([M] +, 100), 390 (22), 388 (62), 352 (19), 324 (22), 323 (25), 315 (36), 297 
(29), 296 (61), 279 (36). HRMS (EI): calcd. for C20H17O6Cl ([M]
+): 388.07082. Found: 
388.07071 and for C20H17O6
37Cl ([M]+): 390.06787. Found: 390.06869.  
Diethyl 6-oxo-9-propyl-6H-benzo[c]chromene-8,10-dicarboxylate (9j): Starting with 
1 (100 mg, 0.5 mmol) and 8j (158 mg, 1.0 mmol), 9j (125 
mg, 62%) was isolated as white solid, m.p. 104-106 °C. 1H 
NMR (300 MHz, CDCl3): δ = 0.95 (t, J = 7.32 Hz, 3H, 
CH3), 1.31-1.38 (m, 6H, 2CH3), 1.53-1.66 (m, 2H, CH2), 
2.91-2.96 (m, 2H, CH2), 4.35 (q, J = 7.12 Hz, 2H, OCH2), 
4.45 (q, 7.17 Hz, 2H, OCH2), 7.17-7.23 (m, 1H, ArH), 7.32 (dd, J = 8.27 Hz, 1.25 Hz, 
1H, ArH), 7.43-7.48 (m, 1H, ArH), 7.82 (dd, J = 8.33 Hz, 1.29 Hz, 1H, ArH), 8.87 (s, 
1H, ArH). 13C NMR (300 MHz, CDCl3): 13.8, 14.2, 14.5 (CH3), 25.1, 33.6 (CH2), 61.7,  
62.4 (OCH2), 116.4 (C), 118.3 (CH), 120.0 (C), 124.5, 125.0 (CH), 131.5 (C), 131.6 
(CH), 131.7, 133.5 (C), 133.9 (CH), 148.3  151.8(C), 160.0, 165.8, 169.5 (CO). IR 
(ATR, cm-1): ν = 2965 (w), 2942 (w), 1722 (s), 1712 (s), 1596 (m), 1434 (w), 1320 (w), 
1241 (s), 1213 (s), 1190 (s), 1016 (s), 748 (s), 735 (s). GC-MS (EI, 70 eV): m/z (%) = 
382 ([M] +, 65), 353 (84), 338 (22), 337 (100), 325 (58), 289 (40). HRMS (EI): calcd. 
for C22H22O6 ([M]
+): 382.14109. Found: 382.14126. 
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Diethyl 6-oxo-9-phenyl-6H-benzo[c]chromene-8,10-dicarboxylate (9k): Starting with 
1 (100 mg, 0.5 mmol) and 8k (200 mg, 1.0 mmol), 9k 
(125 mg, 62%) was isolated as white solid, m.p. 95-97 °C. 
1H NMR (300 MHz, CDCl3): δ = 0.93 (q, J = 7.20 Hz, 6H, 
2CH3), 3.93-4.03 (m, 4H, 2CH2), 7.14-7.21 (m, 3H, ArH), 
7.31-7.33 (m, 4H, ArH), 7.42-7.47 (m, 1H, ArH), 7.80 (dd, 
J = 8.30, 1.24 Hz, 1H, ArH), 8.90 (s, 1H, ArH). 13C NMR 
(300 MHz, CDCl3): δ = 12.3, 12.6 (CH3), 60.5, 61.1 (OCH2), 115.2 (C), 117.3 (CH), 
120.3 (C), 123.6, 124.1 (CH), 126.5 (2CH), 127.3 (CH), 127.4 (C), 127.9 (2CH), 129.1 
(C), 130.7 (CH), 131.5 (C), 131.8 (CH), 135.6, 145.4, 150.8(C), 158.8, 164.6, 167.3 
(CO). IR (ATR, cm-1): ν = 3059 (w), 2980 (w), 1724 (s), 1598 (m), 1444 (m), 1315 
(m), 1277 (m), 1213 (s), 1186 (s), 1112 (s), 1016 (s), 748 (s), 698 (s). GC-MS (EI, 70 
eV): m/z (%) = 416 ([M] +, 100), 371 (20), 343 (30), 325 (80), 213 (19). HRMS (EI): 
calcd. for C25H20O6 ([M]
+): 416.12544. Found: 416.12603. 
Dimethyl-(methoxymethyl)-6-oxo-6H-benzo[c]chromene-8,10-dicarboxylate (9l): 
Starting with 1 (100 mg, 0.5 mmol) and 8l (130 mg, 1.0 mmol), 
9l (139 mg, 77%) was isolated as white solid, m.p. 138-140 °C. 
1H NMR (300 MHz, CDCl3): δ = 3.2 (s, 3H, OCH3), 3.89 (s, 
3H, OCH3), 3.91 (s, 3H, OCH3), 4.81 (s, 2H, CH2), 7.18-7.23 
(m, 1H, ArH), 7.31 (d, J = 8.36 Hz, 1H, ArH), 7.43-7.48 (m, 
1H, ArH), 7.69 (d, 8.26 Hz, 1H, ArH), 8.80 (s, 1H, ArH). 13C NMR (250 MHz, 
CDCl3): δ = 51.7, 51.9, 57.7 (OCH3), 67.7 (CH2), 115.2 (C), 117.3 (CH), 120.6 (C), 
123.6, 124.2 (CH), 129.9 (C), 130.7 (CH), 130.8 (C), 132.1 (CH), 133.0, 142.2  
150.7(C), 158.6, 165.3, 168.4 (CO). IR (ATR, cm-1): ν = 2991 (w), 2945 (w), 2892 (w), 
1714 (s), 1597 (m), 1428 (m), 1299 (m), 1280 (m), 1226 (s), 1205 (s), 1083 (s), 1027 
(m), 917 (m), 748 (s).GC-MS (EI, 70 eV): m/z (%) = 356 ([M]+, 3), 325 (28), 324 (73), 
310 (19), 309 (100), 251 (8), 139 (6). HRMS (EI): calcd. for C19H16O7 ([M]
+): 
356.08905. Found: 356.08889. 
 
O O
OO
OO
O O
OO
OO
O
- 67 - 
 
Methyl 9-ethyl-6-oxo-6H-benzo[c]chromene-8-carboxylate (9g’): Starting with 1 (100 
mg, 0.5 mmol) and 8g (130 mg, 1.0 mmol), 9g’ (42 mg, 30%) 
was isolated as white solid, m.p. 196-198 °C. 1H NMR (300 
MHz, CDCl3): δ = 1.27 (t, J = 7.48 Hz, 3H, CH3), 3.13 (q, J = 
7.47 Hz, 2H, CH2), 3.88 (s, 3H, OCH3), 7.26-7.31 (m, 2H, 
ArH), 7.43-7.48 (m, 1H, ArH), 7.92 (s, 1H, ArH), 8.01-8.04 (m, 
1H, ArH), 8.84 (s, 1H, ArH). 13C NMR (300 MHz, CDCl3): δ = 15.5 (CH3), 28.1 
(CH2), 52.3 (OCH3), 117.3 (C), 117.9 (CH), 118.9 (C), 123.2 (2CH), 124.7 (CH), 129.9 
(C), 131.4, 133.7 (CH), 137.2, 152.0,  153.2 (C), 160.4, 166.3 (CO). IR (ATR, cm-1): ν 
= 2950 (w), 2922 (w), 2851 (w), 1731 (s), 1714 (s), 1607 (s), 1552 (m), 1429 (m), 1296 
(m), 1250 (m), 1227 (s), 1182 (s), 1108 (m), 1112 (m), 754 (s).GC-MS (EI, 70 eV): 
m/z (%) = 282 ([M]+, 87), 251 (100), 178 (25), 139 (12). HRMS (ESI-TOF/MS): calcd. 
for C17H15O4 ([M
+H]+): 283.09649. Found: 283. 09663. 
Dimethyl 9-hydroxy-6-oxo-6H-benzo[c]chromene-8,10-dicarboxylate (11a): Starting 
with 1 (100 mg, 0.5 mmol) and 10a (174 mg, 1.0 mmol), 11a 
(127 mg, 79%) was isolated as light yellow crystalline solid, 
m.p. 219-221 °C. 1H NMR (300 MHz, CDCl3): δ = 2.75 (s, 3H, 
OCH3), 2.86 (s, 3H, OCH3), 7.17-7.23 (m, 1H, ArH), 7.30 (dd, 
J = 8.37, 1.25 Hz, 1H, ArH), 7.44-7.50 (m, 1H, ArH), 7.70 (dd, 
J = 8.32 Hz, J = 1.32 Hz, 1H, ArH), 8.96 (s, 1H, ArH), 11.96 (s, 1H, ArOH). 13C NMR 
(300 MHz, CDCl3): δ = 53.23, 53.28 (OCH3), 113.4, 113.8, 116 (C), 118.4 (CH), 118.6 
(C), 124.7, 125.3, 132.3, 135.4 (CH), 137.2, 152.2 (C), 159.8(COH), 162.9, 167.5, 
169.1 (CO). IR (ATR, cm-1): ν = 3138 (w), 3095 (w), 2954(w), 1723 (s), 1687 (s), 1593 
(m), 1430 (m), 1329 (w), 1290 (m), 1275 (m), 1197 (s), 1176 (s), 1109 (m), 992 (m), 
739 (s). GC-MS (EI, 70 eV): m/z (%) = 328 ([M] +, 94), 296, (62), 265 (100), 238 (98). 
181 (20), 125 (23). HRMS (EI): calcd. for C17H12O7 ([M]
+): 328.05775. Found: 
328.05815. 
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Diethyl 9-hydroxyl-6-oxo-6H-benzo[c]chromene-8,10-dicarboxylate (11b): Starting 
with 1 (100 mg, 0.5 mmol) and 10b (202 mg, 1.0 mmol), 
11b (147 mg, 81%) was isolated as white crystalline solid, 
m.p. 172-174 °C. 1H NMR (300 MHz, CDCl3): δ = 1.33-
1.42 (m, 6H, 2CH3), 4.39-4.52 (m, 4H, 2OCH2), 7.17-7.22 
(m, 1H, ArH), 7.30 (d, J = 7.96 Hz, 1H, ArH), 7.44-7.50 (m, 1H, ArH), 7.80 (d, J = 
8.33 Hz, 1H, ArH), 8.96 (s, 1H, ArH), 11.81 (s, 1H, ArOH). 13C NMR (300 MHz, 
CDCl3): δ = 13.9, 14.1 (CH3), 62.5, 62.8 (OCH2), 113.6, 113.7, 116.1 (C), 118.4 (CH), 
119.0 (C), 124.6, 125.5, 132.2, 135.2 (CH), 136.9  152.1 (C), 159.9(COH), 163.1, 
167.1, 168.8 (CO). IR (ATR, cm-1): ν = 3066 (w), 2977 (w), 1713 (s), 1687 (s), 1592 
(m), 1557 (m), 1446 (w), 1331 (m), 1275 (m), 1294 (s), 1191 (s), 1108 (m), 1015 (m), 
759 (s), 741 (s). GC-MS (EI, 70 eV): m/z (%) = 356 ([M] +, 52), 311 (18), 265 (46), 
238 (100), 311(18), 210 (11), 181 (10). HRMS (EI): calcd. for C19H16O7 ([M]
+): 
356.08905. Found: 356.08960. 
8-acetyl-9-methyl-6H-benzo[c]chromen-6-one (13): Starting with 1 (100 mg, 0.5 
mmol), 12 (100 mg, 1.0 mmol) and K2CO3 (140 mg, 2.0 equiv.) 
dissolved in THF (10 mL). The reaction mixture was allowed to 
stir at 50 °C and monitored by TLC. After the complete 
consumption of the starting material (1), the reaction mixture was 
acidified using HCl (1M) and extracted with ethyl acetate. The combined organic 
layers were dried with Na2SO4 and solvent was removed under reduced pressure. The 
residue was purified by column chromatography (silica gel, heptanes/EtOAc = 3:2) to 
give 13 (65 mg, 54%) as white crystalline solid, m.p. 210-212 °C. 1H NMR (300 MHz, 
CDCl3): δ = 2.63 (s, 3H, CH3), 2.93 (s, 3H, CH3), 7.27-7.32 (m, 2H, ArH), 7.44-7.50 
(m, 1H, ArH), 7.89 (s, 1H, ArH), 8.01 (d, J = 8.40 Hz, 1H, ArH), 8.67 (s, 1H, ArH). 
13C NMR (300 MHz, CDCl3): δ = 21.6, 28.3 (CH3), 116.1 (C), 116.9 (CH), 117.8 (C), 
122.2, 123.7, 124.1, 130.5, 131.2 (CH), 135.8, 136.5, 145.3,151.0(C), 159.5 198.6 
(CO). IR (ATR, cm-1): ν = 3062 (w), 2964 (w), 2922 (w), 1719 (s), 1681 (s), 1607 (s), 
1443 (m), 1430 (m), 1354 (m), 1305 (m), 1175 (s), 1115 (m), 1108 (m), 1035 (m), 892 
(s), 754 (s). GC-MS (EI, 70 eV): m/z (%) = 252 ([M] +, 41), 238(15), 237 (100), 181 
(23), 152 (21). HRMS (ESI-TOF/MS): calcd. for C16H13O3 ([M+H]
+): 253.08592. 
Found: 253.0855. 
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Dimethyl 9-methyl-6H-benzo[c]chromene-8,10-dicarboxylate (14a): Starting with 2 
(194 mg, 1.0 mmol) and 8a (230 mg, 2.0mmol), 13 (5 mg, 2%) 
was isolated as white crystalline solid, m.p. 95-97 °C.  1H NMR 
(300 MHz, CDCl3): δ = 2.48 (s, 3H, CH3), 3.81 (s, 3H, OCH3), 
3.84 (s, 3H, OCH3), 4.92 (s, 2H, CH2), 6.92-6.99 (m, 2H, ArH), 
7.19-7.25 (m, 1H, ArH), 7.48 (dd, J = 8.00 Hz, 0.7 Hz, 1H, 
ArH), 7.69 (s, 1H, ArH). 13C NMR (250 MHz, CDCl3): δ = 17.58 (CH3), 52.1, 52.5 
(OCH3), 68.5 (CH2), 117.9 (CH), 121.7 (C), 122.2, 125.4, 127.5, (CH), 129.3, 
130.5(C), 130.7 (CH), 131.3, 131.3, 137.2, 156.4 (C), 167.2, 170.7 (CO). IR (ATR, cm-
1): ν = 2950 (w), 1720 (s), 1601 (m), 1433 (m), 1227 (s) 1095 (m), 754 (s). GC-MS (EI, 
70 eV): m/z (%) = 312 ([M] +, 100), 281 (29), 253 (23), 165 (23). HRMS (EI): calcd. 
for C18H16O5 ([M]
+): 312.09923. Found: 312.09843. 
Diisopropyl 9-methyl-6H-benzo[c]chromene-8,10-dicarboxylate (14b): Starting with 
2 (194 mg, 1.0 mmol) and 8b (288 mg, 2.0 mmol), 14b (115 
mg, 31%) was isolated as white crystalline solid, m.p. 84-86 
°C.  1H NMR (300 MHz, CDCl3): δ = 1.21 (d, J = 6.34 Hz, 
6H, CH3), 1.30 (d, J = 6.24 Hz, 6H, CH3), 2.48 (s, 3H, CH3), 
4.92 (s, 2H, CH2), 5.14-5.28 (m, 2H, 2OCH) 6.90-6.98 (m, 2H, ArH), 7.18-7.24 (m, 
1H, ArH), 7.61-7.64 (m, 2H, ArH).  13C NMR (250 MHz, CDCl3): δ = 16.3 (CH3), 
20.5, 20.9 (2CH3), 67.6, 67.7 (OCH), 68.6 (CH2) 116.7 (CH), 120.8 (C), 121.0, 124.9, 
125.9 (CH), 128.9, 129.5 (C), 129.5 (CH), 130.2, 131.3, 135.4, 155.4 (C), 165.5, 168.8 
(CO). IR (ATR, cm-1): ν = 2981 (w), 1713 (s), 1703 (s), 1602 (w), 1454 (w), 1231 (s), 
1216 (s), 1095 (s), 1037 (m), 754 (m). GC-MS (EI, 70 eV): m/z (%) = 368 ([M]+, 100), 
309 (40), 283 (89), 239 (30), 165 (31). HRMS (EI): calcd. for C22H24O5 ([M]
+): 
368.16183. Found: 368.16158. 
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Diethyl 9-methyl-6H-benzo[c]chromene-8,10-dicarboxylate (14c): Starting with 2 
(194 mg, 1.0 mmol) and 8c (260 mg, 2.0 mmol), 14c (75 mg, 
22%) was isolated as white crystalline solid, m.p. 106-108 
°C.  1H NMR (300 MHz, CDCl3): δ = 1.21 (t, J = 7.19 Hz, 
3H, CH3), 1.33 (t, J = 7.17 Hz, 3H, CH3),  2.48 (s, 3H, CH3), 
4.26-4.34 (m, 4H, 2OCH2), 4.92 (s, 2H, CH2), 6.91-6.99 (m, 
2H, ArH), 7.18-7.24 (m, 1H, ArH), 7.55 (dd, J= 7.99 Hz; 1.45 Hz, 1H, ArH), 7.66 (s, 
1H, ArH). 13C NMR (250 MHz, CDCl3): δ = 13.8, 14.2, 17.4, (CH3), 61.1, 61.7 
(OCH2), 68.5 (CH2), 117.8 (CH), 121.7 (C), 122.1, 125.6, 127.2 (CH), 129.7, 130.2 
(C), 130.6 (CH), 131.2, 132.0, 136.8, 156.4 (C), 166.9, 170.3 (CO). IR (ATR, cm-1): ν 
= 2974 (w), 1717 (s), 1706 (s), 1600(w), 1445 (w), 1235 (s), 1181 (m), 1150 (m), 1017 
(m), 774 (s), 764 (s). GC–MS (EI, 70 eV): m/z (%) = 340 ([M] +, 100), 295 (34), 267 
(21), 165 (19). HRMS (EI): calcd. for C20H20O5 ([M]
+): 340.13053. Found: 340.12994. 
Diallyl 9-methyl-6H-benzo[c]chromene-8,10-dicarboxylate (14e):Starting with 2 (194 
mg, 1.0 mmol) and 8e (284 mg, 2.0 mmol), 14c (140 
mg, 38 %) was isolated as white crystalline solid, m.p. 
70-72 °C.  1H NMR (250 MHz, CDCl3): δ = 2.49 (s, 3H, 
CH3), 4.73-4.75 (m, 4H, 2OCH2), 4.92 (s, 2H, CH2), 
5.16-5.38 (m, 4H, 2CH2), 5.76-6.05 (m, 2H, 2CH), 6.89-6.99 (m, 2H, ArH), 7.18-7.25 
(s, 1H, ArH), 7.53 (dd, J = 7.94 Hz; 0.70 Hz, 1H, ArH), 7.70 (s, 1H, ArH). 13C NMR 
(300 MHz, CDCl3): δ = 17.5 (CH3), 65.8, 66.4, 68.5 (CH2), 117.9 (CH), 118.7, 119.8 
(CH2), 121.6 (C), 122.2, 125.7, 127.4 (CH), 129.3, 130.6 (C), 130.7, 131.0 (CH), 
131.3, 131.8 (C), 131.9 (CH), 137.2, 156.4 (C), 166.4, 169.9 (CO). IR (ATR, cm-1): ν = 
2918 (w), 1721 (s), 1711 (s), 1598(w), 1444 (w), 1225 (m), 1200 (s), 1173 (s), 1036 
(m), 761 (s). GC-MS (EI, 70 eV): m/z (%) = 364 ([M] +, 100), 307 (33), 281 (19), 
237(15) 165 (21). HRMS (EI): calcd. for C22H20O5 ([M]
+): 364.13053. Found: 
364.12994. 
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Di-tert-butyl9-methyl-6H-benzo[c]chromene-8,10-dicarboxylate (14m): Starting with 
2 (194 mg, 1.0 mmol) and 8m (316 mg, 2.0 mmol), 14m (140 
mg, 35 %) was isolated as white crystalline solid, m.p. 110-
112 °C.  1H NMR (300 MHz, CDCl3): δ = 1.48 (s, 9H, 3CH3), 
1.52 (s, 9H, 3CH3), 2.47 (s, 3H, CH3), 4.91 (s, 2H, CH2), 
6.90-6.97 (m, 2H, ArH), 7.17-7.23 (m, 1H, ArH), 7.50 (s, 1H, ArH), 7.77 (dd, J = 7.78 
Hz; 0.81Hz, 1H, ArH).  13C NMR (250 MHz, CDCl3): δ = 17.2 (CH3), 27.9, 28.2 
(3CH3) 68.7(CH2) 81.7, 83.1 (C), 117.5, 121.8 (CH), 122.0 (C), 126.3, 126.6 (CH), 
129.1 (C), 130.3 (CH), 131.2, 131.8, 133.3, 135.6, 156.3 (C), 166.7, 169.5 (CO). IR 
(ATR, cm-1): ν = 2972 (w), 1715 (s), 1699 (s), 1602(w), 1465 (w), 1366 (m), 1240 (s), 
1148 (s), 755 (s). GC-MS (EI, 70 eV): m/z (%) = 396 ([M] +, 24), 284 (100), 283 (57), 
239 (18), 165 (10). HRMS (EI): calcd. for C24H28O5 ([M]
+): 396.19313. Found: 
396.19291. 
Dimethyl 9-hydroxyl-6H-benzo[c]chromene-8,10-dicarboxylate (16a):Starting with 2 
(194 mg, 1.0 mmol) and 10a (348 mg, 2.0 mmol), 16a (165 mg, 
52%) was isolated as white crystalline solid, m.p. 239-230 °C.  
1H NMR (300 MHz, CDCl3): δ = 3.83 (s, 3H, OCH3), 3.87 (s, 
3H, OCH3), 4.84 (d, J = 0.39 Hz, 2H, CH2), 6.90-6.96 (m, 2H, 
ArH), 7.20-7.25 (m, 1H, ArH), 7.44-7.47 (m, 1H, ArH), 7.62 (s, 
1H, ArH), 11.08 (s, 1H, ArOH).  13C NMR (250 MHz, CDCl3): δ = 52.6, 52.7 (OCH3), 
68.3 (CH2), 110.9 (C), 118.0 (CH), 119.1 (C), 121.2 (C), 122.2 (CH), 124.4 (C), 125.9, 
126.7, 131.4 (CH), 134.2, 156.6 (C), 158.9 (COH), 168.2, 169.7 (CO). IR (ATR, cm-1): 
ν = 3099(w), 2949 (w) 1723 (s), 1667 (s), 1621(m), 1605 (m), 1590 (m), 1438 (s), 1347 
(m), 1236 (s), 1216 (s), 1172 (s), 1153 (s), 996 (s), 770(s), 750 (s), 738(s). GC–MS (EI, 
70 eV): m/z (%) = 314 ([M]+, 94), 282 (100), 281 (70), 251 (57), 224 (62), 223 (36)139 
(76). HRMS (EI): calcd. for C17H14O6 ([M]
+): 314.07849. Found: 314.07789. 
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Diethyl 9-hydroxyl-6H-benzo[c]chromene-8,10-dicarboxylate (16b):Starting with 2 
(194 mg, 1.0 mmol) and 10b (404 mg, 2.0 mmol), 16b (222 
mg, 65%) was isolated as white crystalline solid, m.p. 145-
147 °C.  1H NMR (300 MHz, CDCl3): δ = 1.22 (t, J = 7.13 
Hz, 3H, CH3), 1.31 (t, J = 7.13 Hz, 3H, CH3), 4.28-4.37 (m, 
4H, 2OCH2), 4.83 (s, 2H, CH2), 6.88-6.94 (m, 2H, ArH), 7.17-7.23 (m, 1H, ArH), 7.52 
(dd, J = 7.86 Hz, 0.61 Hz, 1H, ArH), 7.61 (s, 1H, ArH), 11.15 (s, 1H, ArOH).  13C 
NMR (250 MHz, CDCl3): δ = 12.8, 13.1 (CH3), 60.8, 60.9 (OCH2), 67.3 (CH2), 110.1 
(C), 116.9 (CH), 118.5, 120.2 (C), 121.0 (CH), 123.3 (C), 125.3, 125.5 (CH), 130.2 
(CH), 132.9, 155.6 (C), 157.9 (COH), 166.8, 168.3 (CO). IR (ATR, cm-1): ν = 3085(w), 
2970 (w) 1720 (s), 1666 (s), 1621(m), 1605 (m), 1594 (m), 1404 (m), 1330 (m), 1247 
(s), 1216 (s), 1182 (s), 1019 (s), 770(s). GC-MS (EI, 70 eV): m/z (%) = 342 ([M]+, 73), 
296 (52), 251 (41), 224 (100), 139 (48). HRMS (EI): calcd. for C19H18O6 ([M]
+): 
342.10979. Found: 342.10955. 
Di-tert-butyl 9-hydroxyl-6H-benzo[c]chromene-8,10-dicarboxylate (16c): Starting 
with 2 (194 mg, 1.0 mmol) and 10c (516 mg, 2.0 mmol), 16c 
(250 mg, 62%) was isolated as white crystalline solid, m.p. 
138-140 °C.  1H NMR (300 MHz, CDCl3): δ = 1.51 (s, 9H, 
3CH3), 1.52 (s, 9H, 3CH3), 4.85 (d, J = 0.56 Hz, 2H, CH2), 
6.89-6.95 (m, 2H, ArH), 7.17-7.24 (m, 1H, ArH), 7.5 (s, 1H, ArH), 7.76 (dd, J = 7.8 
Hz, 1.63 Hz, 1H, ArH), 11.26 (s,1H,ArOH).  13C NMR (300 MHz, CDCl3): δ = 26.9 
(3CH3), 27.1 (3CH3), 67.5 (CH2) 81.9, 82.4, 111.3 (C), 116.7 (CH), 120.2, 120.5 (C), 
120.8 (CH), 122.8 (C), 125.1, 125.8, 130.0 (CH), 131.8, 155.5 (C), 158.1 (COH), 
166.1, 168.0 (CO). IR (ATR, cm-1): ν = 3006 (w), 2981 (w) 1718 (s), 1660 (s), 
1618(m), 1605 (m), 1591 (m), 1449 (m), 1391 (m), 1365 (s), 1248(s), 1143 (s), 1038 
(s), 796 (s), 773(s). GC–MS (EI, 70 eV): m/z (%) = 297 ([M] +, 100), 298 (56), 139 
(10), 253 (8). HRMS (ESI-TOF/MS): calcd. for C23H26O6 ([M+H]
+): 399.18022. 
Found: 399.17966.  
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Dimethyl 9-hydroxyl-6-phenyl-6H-benzo[c]chromene-8,10-dicarboxylate (17a): 
Starting with 3 (270 mg, 1.0 mmol) and 10a (348 mg, 2.0 
mmol), 17a (210 mg, 54%) was isolated as white crystalline 
solid, m.p. 208-210 °C.  1H NMR (300 MHz, CDCl3): δ = 3.79 
(s, 3H, OCH3), 3.86 (s, 3H, OCH3), 5.91 (s, 1H, CH-Ph), 6.88-
6.97 (m, 2H, ArH), 7.18-7.29 (m, 7H, ArH), 7.48 (dd, J = 7.94 
Hz, 1.4 Hz, 1H, ArH), 11.15 (s, 1H, ArOH). 13C NMR (300 MHz, CDCl3): δ = 52.6, 
52.8 (OCH3), 79.4 (CH), 111.0 (C), 118.7 (CH), 119.2, 121.2 (C), 122.3, 125.8 (CH), 
127.3 (C), 128.1(2CH), 128.2 (CH), 128.6 (2CH), 128.7, 131.5 (CH), 134.4, 138.2, 
155.3, 158.9(COH), 168.4, 169.8 (CO). IR (ATR, cm-1): ν = 3003(w), 2953 (w) 1727 
(s), 1674 (s), 1619(m), 1604 (m), 1589 (m), 1440 (s), 1349 (m), 1237 (s), 1155(s), 1143 
(s), 994 (m), 989 (m) 796 (s), 773(s), 759 (s), 702 (s). GC-MS (EI, 70 eV): m/z (%) = 
390 ([M] +, 60), 313 (60), 282 (18), 281 (100), 213 (18).  HRMS (EI): calcd. for 
C23H18O6 ([M]
+): 390.10979. Found: 390.10943. 
Diethyl 9-hydroxyl-6-phenyl-6H-benzo[c]chromene-8,10-dicarboxylate (17b): 
Starting with 3 (270 mg, 1.0 mmol) and 10b (404 mg, 2.0 
mmol), 17b (258 mg, 60%) was isolated as white 
crystalline solid, m.p. 143-145 °C.1H NMR (300 MHz, 
CDCl3): δ = 1.25 (td 7.14 Hz, 0.92 Hz, 6H, 2CH3), 4.22-
4.31 (m, 2H, CH2), 4.36 (q, 7.14 Hz, 2H, CH2), 5.95 (s, 
1H, CH-Ph), 6.86-6.95 (m, 2H, ArH), 7.16-7.27 (m, 6H, ArH), 7.33 (d, 0.75 Hz, 1H, 
ArH), 7.54 (dd, 8.03 Hz, 0.69 Hz, 1H, ArH), 11.20 (s, 1H, ArOH). 13CNMR (300 
MHz, CDCl3): δ = 13.9, 14.0 (CH3), 61.88, 62.0 (OCH2) 79.2 (CH),111.3 (C), 118.6 
(CH), 119.6, 121.3 (C), 122.1, 126.0 (CH), 126.9 (C), 128.1 (2CH), 128.2, 128.5, 
(CH), 128.6 (2CH), 131.4 (CH), 134.0, 138.4  155.1(C), 159.0 (COH), 168.0, 169.4 
(CO). IR (ATR, cm-1): ν = 3032(w), 2979 (w) 1730 (s), 1666 (m), 1620(w), 1604 (w), 
1461 (m), 1302(m), 1237 (s), 1155(s), 1148 (s), 1021(s), 762 (s) 702 (s). GC-MS (EI, 
70 eV): m/z (%) = 418 ([M] +, 83), 341 (90), 327 (23), 300 (40), 299 (27)295 (100), 
271 (14), 242 (12).  HRMS (EI): calcd. for C25H22O6 ([M]
+): 418.14109. Found: 
418.14049. 
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Di-tert-butyl 9-hydroxyl-6-phenyl-6H-benzo[c]chromene-8,10-dicarboxylate (17c): 
Starting with 3 (270 mg, 1.0 mmol) and 10c (516 mg, 2.0 
mmol), 17c (304 mg, 66%) was isolated as white crystalline 
solid, m.p. 163-165 °C.  1H NMR (300 MHz, CDCl3): δ = 
1.43 (s, 9H, 3CH3), 1.52 (s, 9H, 3CH3), 5.93 (s, 1H, CH-Ph), 
6.84-6.93 (m, 2H, ArH), 7.13-7.26 (m, 7H, ArH), 7.76 (dd, J 
= 7.95 Hz, 1.36 Hz, 1H, ArH), 11.24 (s, 1H,ArOH). 
13CNMR (300 MHz, CDCl3): δ = 26.9, 26.9 (3CH3), 78.2 (CH), 82.0, 82.3, 111.4 (C), 
117.3 (CH), 120.2, 120.5 (C), 120.8 (CH), 125.3 (C), 125.6, 126.9 (CH), 127.0, 127.3 
(2CH), 127.4, 130.14 (CH), 131.8, 137.5 153.9(C), 158.0 (COH), 166.1, 167.9 (CO). 
IR (ATR, cm-1): ν = 3003(w), 2971 (w) 1716 (s), 1670 (s), 1605 (m), 1454 (m), 
1355(s), 1243 (s), 1142(s), 764 (s), 703 (s). GC-MS (EI, 70 eV): m/z (%) = 297 ([M] +, 
100), 374 (30), 298 (22), 373 (18).  HRMS (ESI-TOF/MS): calcd. for C29H30O6 
([M+Na]+): 497.19346. Found: 497.1940. 
Methyl 6-oxo-9-p-tolyl-6H-benzo[c]chromene-8-carboxylate (21a): Starting with 1 
(200 mg, 1.0 mmol), K2CO3 (200 mg, 1.5 equiv.), 
PdCl2(PPh3)2(28 mg, 4 mol%), CuI (13 mg, 7mol%), 18a (170 
mg, 1.5 mmol) and 20a (174 mg, 1.5 mmol), 21a (165mg, 48%) 
was isolated as white crystalline solid, m.p. 139-140 °C.  1H 
NMR (300 MHz, CDCl3): δ = 2.36 (s, 3H, CH3), 3.68 (s, 3H, 
OCH3), 7.21-7.32 (m, 6H, ArH), 7.42-7.48 (m, 1H, ArH), 7.97-
8.00 (m, 2H, ArH), 8.77(s, 1H, ArH). 13C NMR (250 MHz, CDCl3): δ = 20.2 (CH3), 
51.3 (OCH3), 116.2 (C), 116.9 (CH), 118.6 (C), 122.2, 123.2, 123.7 (CH), 127.0, 128.1 
(2CH), 130.2 (C), 130.4, 131.7 (CH), 135.6, 135.9, 137.3, 147.8, 150.9(C), 159.3, 
166.1 (CO). IR (ATR, cm-1): ν = 2954 (w), 2918 (w), 1731 (s), 1606(s), 1227 (m), 
1183 (m) 1086 (m), 910(m), 815 (m), 746 (s). GC-MS (EI, 70 eV): m/z (%) = 344 
([M]+, 100), 313 (91), 269 (17), 239 (14), 226 (15). HRMS (EI): calcd. for C22H16O4 
([M]+): 344.10431. Found: 344.10405. 
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Ethyl 6-oxo-9-p-tolyl-6H-benzo[c]chromene-8-carboxylate (21b): Starting with 1 
(200 mg, 1.0 mmol), K2CO3 (200 mg, 1.5 equiv.), 
PdCl2(PPh3)2(28 mg, 4 mol%), CuI (13 mg, 7mol%), 18a 
(170 mg, 1.5 mmol) and 20b (200 mg, 1.5 mmol), 21b ( 
170mg, 47%) was isolated as white crystalline solid, m.p. 
156-157 °C. 1H NMR (300 MHz, CDCl3): δ =  1.08 (t, J = 
7.14 Hz, 3H, CH3), 2.35 (s, 3H, CH3), 4.13 (q, J = 7.14 Hz, 
2H, OCH2), 7.20-7.31 (m, 6H, ArH), 7.41-7.47 (m, 1H, ArH), 7.96-7.99 (m, 2H, ArH), 
8.75(s, 1H, ArH). 13C NMR (250 MHz, CDCl3): δ = 13.8, 21.2 (CH3), 61.4 (OCH2), 
117.2 (C), 117.9 (CH), 119.6 (C), 123.2, 124.1, 124.7 (CH), 128.1, 129.0 (2CH), 131.4 
(CH), 131.8 (C), 132.5 (CH), 136.5, 137.1, 138.2, 148.7 151.9 (C), 160.3, 166.8 (CO). 
IR (ATR, cm-1): ν = 2947 (w), 2921 (w), 1731 (s), 1715 (s), 1613(s), 1292 (m), 1228 
(s), 1184 (m) 1083 (m), 929 (m), 818 (m), 745 (s), 731 (m). GC-MS (EI, 70 eV): m/z 
(%) = 358 ([M]+,88), 330 (15), 313 (100), 239 (18) 226 (20). HRMS (ESI-TOF): calcd. 
for C23H19O4 ([M+H]
+): 359.12779. Found: 359.12757. 
8-Acetyl-9-p-tolyl-6H-benzo[c]chromen-6-one (21c): Starting with 1 (200 mg, 1.0 
mmol), K2CO3 (200 mg, 1.5 equiv.), PdCl2(PPh3)2 (28 mg, 4 
mol%), CuI (13 mg, 7mol%), 18a (170 mg, 1.5 mmol) and 20c 
(150 mg, 1.5 mmol), 21c (130mg, 43%) was isolated as white 
crystalline solid, m.p. 153-155 °C. 1H NMR (300 MHz, CDCl3): δ 
= 2.09 (s, 3H, CH3), 2.37 (s, 3H, CH3), 7.23-7.32 (m, 6H, ArH), 
7.42-7.48 (m, 1H, ArH), 7.98-8.01 (m, 2H, ArH), 8.49 (s, 1H, 
ArH). 13C NMR (250 MHz, CDCl3): δ = 21.2, 30.1 (CH3), 117.3 
(C), 117.9 (CH), 119.8 (C), 123.2, 123.7, 124.7, (CH), 128.5, 129.7 (2CH), 130.6, 
131.3 (CH), 136.2, 136.5, 139.0, 141.0, 146.8  151.8(C), 160.4, 202.2 (CO). IR (ATR, 
cm-1): ν = 2922 (w), 1730 (s), 1674 (s), 1602 (s), 1210 (m), 1113 (m), 822 (m), 743 (s). 
GC-MS (EI, 70 eV): m/z (%) = 328 ([M]+, 58), 313 (100), 269 (22), 239 (18), 220 (20). 
HRMS (ESI-TOF): calcd. for C22H17O3  ([M+H]
+): 329.11722. Found: 329.11748. 
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8-Acetyl-9-phenyl-6H-benzo[c]chromen-6-one (21d): Starting with 1 (200 mg, 1.0 
mmol), K2CO3 (200 mg, 1.5 equiv.), PdCl2(PPh3)2(28 mg, 4 
mol%), CuI (13 mg, 7mol%), 18b (150 mg, 1.5 mmol) and 20c 
(150 mg, 1.5 mmol), 21d ( 132 mg, 42%) was isolated as white 
crystalline solid, m.p. 105-107 °C. 1H NMR (300 MHz, CDCl3): δ 
= 2.09 (s, 3H, CH3) 7.25-7.37 (m, 4H, ArH), 7.40-7.48 (m, 4H, 
ArH), 7.99-8.02 (m, 2H, ArH), 8.51 (s, 1H, ArH).13C NMR (250 MHz, CDCl3): δ = 
30.1 (CH3), 117.2 (C), 118.0 (CH), 120.0 (C), 123.2, 123.9, 124.7, (CH), 128.6 (2CH), 
128.9 (2CH), 128.9, 130.7, 131.4 (CH), 136.2, 139.4, 140.9, 146.8, 151.9(C), 160.3, 
201.9 (CO). IR (ATR, cm-1): ν = 2922 (w), 1733 (s), 1684 (s), 1607(s), 1215 (m), 1184 
(m), 1069 (w), 822 (m), 753 (s), 703 (s). GC-MS (EI, 70 eV): m/z (%) = 314 ([M]+, 
56), 299 (100), 255 (23), 226 (30), 213 (22). HRMS (EI): calcd. for C21H14O3 ([M]
+): 
314.09375. Found: 314.09378. 
Ethyl 6-oxo-9-phenyl-6H-benzo[c]chromene-8-carboxylate (21e): Starting with 1 
(200 mg, 1.0 mmol), K2CO3 (200 mg, 1.5 equiv.), 
PdCl2(PPh3)2(28 mg, 4 mol%), CuI (13 mg, 7mol%), 18b 
(150 mg, 1.5 mmol) and 20b (200 mg, 1.5 mmol), 21d (160 
mg, 46%) was isolated as white crystalline solid, m.p. 119-
121 °C. 1H NMR (300 MHz, CDCl3): δ= 1.03 (t, J = 7.14 Hz, 
3H, CH3), 4.10 (q, J = 7.14 Hz, 2H, CH2), 7.23-7.34 (m, 4H, 
ArH), 7.35-7.47 (m, 4H, ArH), 7.96-7.99 (m, 2H, ArH), 8.77(s, 1H, ArH). 13C NMR 
(250 MHz, CDCl3): δ = 13.1 (CH3), 61.4 (OCH2), 116.2 (C), 116.9 (CH), 118.8 (C), 
122.3, 123.1, 123.7 (CH), 127.1 (2CH), 127.2 (CH), 127.3 (2CH), 130.4 (CH), 130.8 
(C), 131.6 (CH), 135.5, 139.1, 147.7, 150.9 (C), 159.2, 165.7 (CO). IR (ATR, cm-1): ν 
= 2977 (w), 2927 (w), 1724 (s), 1709 (s), 1613(s), 1244 (m), 1226 (s), 1185 (m) 1087 
(m), 923 (m), 748 (s), 701 (m). GC-MS (EI, 70 eV): m/z (%) = 344 ([M]+, 79),  300 
(22), 299 (100), 255 (17), 226 (24). HRMS (EI): calcd. for C22H16O4 ([M]
+): 
344.10431. Found: 344.10390. 
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Methyl 6-oxo-9-phenyl-6H-benzo[c]chromene-8-carboxylate (21f): Starting with 1 
(200 mg, 1.0 mmol), K2CO3 (200 mg, 1.5 equiv.), 
PdCl2(PPh3)2(28 mg, 4 mol%), CuI (13 mg, 7mol%), 18b (150 
mg, 1.5 mmol) and 20a (174 mg, 1.5 mmol), 21f (155 mg, 47%) 
was isolated as white crystalline solid, m.p. 185-187 °C. 1H 
NMR (250 MHz, CDCl3): δ = 3.66 (s, 3H, OCH3), 7.24-7.34 (m, 
4H, ArH), 7.36-7.50 (m, 4H, ArH), 7.98-8.01 (m, 2H, ArH), 
8.81(s, 1H, ArH). 13C NMR (250 MHz, CDCl3): δ = 52.3 (OCH3), 117.2 (C), 118.0 
(CH), 119.8 (C), 123.3, 124.3, 124.8 (CH), 128.1 (2CH), 128.3 (3CH), 131.2 (C), 
131.5, 132.8 (CH), 136.7, 139.9, 148.8, 152.01(C), 160.2, 167.0 (CO). IR (ATR, cm-1): 
ν = 2947 (w), 1716 (s), 1608(m), 1228 (s), 1184 (m) 1083 (m), 977 (m), 751 (s), 703 
(m). GC-MS (EI, 70 eV): m/z (%) = 330 ([M]+, 97), 299 (100), 271 (8), 255 (20), 226 
(25). HRMS (EI): calcd. for C21H14O3 ([M]
+): 330.08866. Found: 330.08840. 
Isopropyl 6-oxo-9-phenyl-6H-benzo[c]chromene-8-carboxylate (21g): Starting with 1 
(200 mg, 1.0 mmol), K2CO3 (200 mg, 1.5 equiv.), 
PdCl2(PPh3)2(28 mg, 4 mol%), CuI (13 mg, 7mol%), 18b (150 
mg, 1.5 mmol) and 20d (200 mg, 1.5 mmol), 21f ( 158 mg, 
44%) was isolated as white crystalline solid, m.p. 124-126 °C. 
1H NMR (300 MHz, CDCl3): δ= 1.03 (d, J = 6.27 Hz, 6H, 
2CH3), 4.97 (sept, J = 6.27 Hz, 1H, OCH), 7.24-7.34 (m, 4H, 
ArH), 7.35-7.48 (m, 4H, ArH), 7.97-8.01 (m, 2H, ArH), 8.75(s, 1H, ArH). 13C NMR 
(250 MHz, CDCl3): δ = 21.4 (2CH3), 69.3 (OCH), 117.2 (C), 117.9 (CH), 119.8 (C), 
123.2, 124.0, 124.7 (CH), 128.2 (3CH),128.3 (2CH), 131.4, 132.4 (CH), 132.5, 136.4, 
140.2, 148.5, 151.9 (C), 160.3, 166.4 (CO). IR (ATR, cm-1): ν = 2983 (w), 2971 (w), 
2933 (w), 1716 (s), 1700 (s), 1614(s), 1247 (m), 1229 (s), 1106 (m) 1088(m), 923(w), 
751 (s), 701 (m). GC-MS (EI, 70 eV): m/z (%) = 358 ([M]+, 82), 316 (100), 300 (29), 
299 (97), 255(14), 226 (28). HRMS (EI): calcd. for C23H18O4 ([M]
+): 358.11996. 
Found: 358.11963. 
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Isopropyl 6-oxo-9-propyl-6H-benzo[c]chromene-8-carboxylate (21h): Starting with 1 
(200 mg, 1.0 mmol), K2CO3 (200 mg, 1.5 equiv.), 
PdCl2(PPh3)2(28 mg, 4 mol%), CuI (13 mg, 7mol%), 18c 
(100 mg, 1.5 mmol) and 20d (200 mg, 1.5 mmol), 21h ( 134 
mg, 41%) was isolated as white crystalline solid, m.p. 93°C-
95 °C. 1H NMR (300 MHz, CDCl3): δ =  0.96 (t, J = 7.35 
Hz, 3H, CH3), 1.33 (d, , J = 6.27 Hz, 6H, 2CH3), 1.58-1.70 
(m, 2H, CH2), 3.01-3.06 (m, 2H, CH2), 5.20 (sept., J = 6.27 Hz,1H, OCH), 7.24-7.29 
(m, 2H, ArH), 7.40-7.46 (m, 1H, ArH), 7.86 (s, 1H, ArH),  7.98-8.01 (m, 1H, ArH), 
8.75(s, 1H, ArH). 13C NMR (250 MHz, CDCl3): δ = 14.1 (CH3), 21.8 (2CH3), 24.8, 
39.9 (CH2), 69.0 (OCH), 117.3 (C), 117.8 (CH), 118.8 (C), 123.2, 123.8, 124.6, 131.2, 
133.2 (CH), 136.7 (C), 151.3 (2C), 151.9 (C), 160.5, 165.7 (CO). IR (ATR, cm-1): ν = 
2958 (w), 2931 (w), 2870 (w), 1722 (s), 1609 (s), 1242 (s), 1234 (s), 1189 (m), 1102 
(m) 757 (s). GC-MS (EI, 70 eV): m/z (%) = 324 ([M] +, 19), 282 (100), 267 (57), 265 
(41), 249 (17), 152 (17), HRMS (EI): calcd. for C20H20O4 ([M]
+): 324.13561. Found: 
324.13556. 
Methyl 6-oxo-9-propyl-6H-benzo[c]chromene-8-carboxylate (21i): Starting with 1 
(200 mg, 1.0 mmol), K2CO3 (200 mg, 1.5 equiv.), 
PdCl2(PPh3)2(28 mg, 4 mol%), CuI (13 mg, 7mol%), 18c (100 
mg, 1.5 mmol) and 20a (174 mg, 1.5 mmol), 21i ( 114 mg, 
38%) was isolated as white crystalline solid, m.p. 100°C-102 
°C. 1H NMR (300 MHz, CDCl3): δ =  0.96 (t, J = 7.38 Hz, 3H, 
CH3), 1.57-1.70 (m, 2H, CH2), 3.03-3.08 (m, 2H, CH2), 3.86 (s, 
3H, OCH3),  7.25-7.29 (m, 2H, ArH), 7.40-7.46 (m, 1H, ArH), 7.87 (s, 1H, ArH),  7.99 
(d, J = 6Hz, 1H, ArH), 8.81(s, 1H, ArH).13C NMR (300 MHz, CDCl3): δ = 14.1 (CH3), 
24.7, 36.9 (CH2), 52.2 (OCH3), 117.2 (C), 117.9 (CH), 118.8 (C), 123.2, 123.9, 124.6, 
(CH), 130.0 (C), 131.3, 133.6 (CH), 136.9, 151.7, 151.9 (C), 160.4, 166.3 (CO). IR 
(ATR, cm-1): ν = 2955 (w), 2929 (w), 2868 (w), 1714 (s), 1608 (s), 1229 (s), 1181 (s), 
1072 (m), 907(w), 747 (s). GC-MS (EI, 70 eV): m/z (%) = 296 ([M] +, 60), 265 100), 
266 (20), 249 (34), 165 (11), 152 (16). HRMS (EI): calcd. for C18H16O4 ([M]
+): 
296.10431. Found: 296.10438. 
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Ethyl 6-oxo-9-propyl-6H-benzo[c]chromene-8-carboxylate (21j): Starting with 1 (200 
mg, 1.0 mmol), K2CO3 (200 mg, 1.5 equiv.), 
PdCl2(PPh3)2(28 mg, 4 mol%), CuI (13 mg, 7mol%), 18c 
(100 mg, 1.5 mmol) and 20b (200 mg, 1.5 mmol), 21j ( 130 
mg, 43%) was isolated as white crystalline solid, m.p. 90 °C-
92 °C. 1H NMR (300 MHz, CDCl3): δ =  0.96 (t, J = 7.35 
Hz, 3H, CH3), 1.36 (t, J = 7.14 Hz, 3H, CH3), 1.58-1.70 (m, 
2H, CH2), 3.03-3.08 (m, 2H, CH2), 4.33 (q, J = 7.14 Hz, 2H,OCH2),  7.25-7.29 (m, 2H, 
ArH), 7.41-7.46 (m, 1H, ArH), 7.87 (s, 1H, ArH),  8.00 (d, J = 7.8Hz, 1H,ArH), 8.80 
(s, 1H, ArH). 13C NMR (300 MHz, CDCl3): δ = 14.1, 14.2 (CH3), 24.7, 36.9(CH2), 61.3 
(OCH2), 117.2 (C), 117.9 (CH), 118.8 (C), 123.2, 123.9, 124.6 (CH), 130.6 (C), 131.3, 
133.5 (CH), 136.8,151.5, 151.9(C),160.4, 166.0 (CO). IR (ATR, cm-1): ν = 2959 (w), 
2930 (w), 2870 (w), 1731 (s), 1707 (s), 1608 (s), 1227 (s), 1179 (s), 1068 (m), 750 (s). 
GC-MS (EI, 70 eV): m/z (%) = 310 ([M] +, 63), 267 (23), 265 (100), 249 (27), 165 
(16), 152 (20). HRMS (EI): calcd. for C19H18O4 ([M]
+): 310.11996. Found: 310.11984. 
8-Acetyl-9-propyl-6H-benzo[c]chromen-6-one (21k): Starting with 1 (200 mg, 1.0 
mmol), K2CO3 (200 mg, 1.5 equiv.), PdCl2(PPh3)2 (28 mg, 4 
mol%), CuI (13 mg, 7mol%), 18c (100 mg, 1.5 mmol) and 20c 
(150 mg, 1.5 mmol), 21k (115mg, 41%) was isolated as white 
crystalline solid, m.p. 113°C-115 °C. 1H NMR (300 MHz, 
CDCl3): δ =  0.94 (t, J = 7.38 Hz, 3H, CH3), 1.54-1.66 (m, 2H, 
CH2), 2.61 (s, 3H, CH3), 2.93- 2.98 (m, 2H, CH2), 7.25-7.30 (m, 2H, ArH), 7.42-7.47 
(m, 1H, ArH), 7.87 (s, 1H, ArH),  7.99-8.02 (m, 1H, ArH), 8.5 (s, 1H, ArH). 13C NMR 
(300 MHz, CDCl3): δ = 14.1 (CH3),  24.7 (CH2), 29.8 (CH3), 36.6 (CH2), 117.2 (C), 
117.9 (CH), 118.7 (C), 123.2, 124.2, 124.7, 131.4, 131.8 (CH), 136.6, 138.0, 150.5  
151.9(C) 160.5, 200.1 (CO). IR (ATR, cm-1): ν = 2964 (w), 2919 (w), 2871 (w), 1721 
(s), 1682 (s), 1607 (s), 1229 (s), 1174 (s), 1082 (m), 751 (s). GC-MS (EI, 70 eV): m/z 
(%) = 280 ([M] +, 13), 266 (19), 265 (100), 178 (11), 152 (9). HRMS (EI): calcd. for 
C18H16O3 ([M]
+): 280.10940. Found: 280.10979. 
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8-Acetyl-9-propyl-6H-benzo[c]chromen-6-one (21l): Starting with 1 (200 mg, 1.0 
mmol), K2CO3 (200 mg, 1.5 equiv.), PdCl2(PPh3)2 (28 mg, 4 
mol%), CuI (13 mg, 7mol%), 18d (140 mg, 1.5 mmol) and 20c 
(150 mg, 1.5 mmol), 21l (130mg, 43%) was isolated as white 
crystalline solid, m.p. 60 °C-62 °C. 1H NMR (250 MHz, CDCl3): 
δ =  0.81-0.86 (m, 3H, CH3), 1.26-1.36 (m, 4H, 2CH2), 1.51- 1.62 
(m, 2H, CH2), 2.61 (s, 3H, CH3), 2.94-3.00 (m, 2H, CH2), 7.19-
7.32 (m, 2H, ArH), 7.42-7.49 (m, 1H, ArH), 7.88 (s, 1H, ArH),  
8.00-8.03 (m, 1H, ArH), 8.59 (s, 1H, ArH). 13C NMR (250 MHz, CDCl3): δ = 14.0 
(CH3), 22.4 (CH2), 29.7 (CH3), 31.3, 31.9, 34.7 (CH2), 117.2 (C), 117.9 (CH), 118.6 
(C), 123.2, 124.2, 124.7, 131.4, 131.8 (CH), 136.7, 137.9, 150.8  151.9(C), 160.5, 
200.1 (CO). IR (ATR, cm-1): ν = 2952 (w), 2922 (w), 2854 (w), 1739 (s), 1683 (s), 
1609 (s), 1229 (s), 1175 (s), 1077 (m), 749 (s). GC-MS (EI, 70 eV): m/z (%) = 308 
([M] +, 11), 294 (20), 293 (100), 265 (15), 152 (10). HRMS (EI): calcd. for C20H20O3 
([M]+): 308.14070. Found: 308.14118. 
Methyl 6-oxo-9-pentyl-6H-benzo[c]chromene-8-carboxylate (21m): Starting with 1 
(200 mg, 1.0 mmol), K2CO3 (200 mg, 1.5 equiv.), 
PdCl2(PPh3)2(28 mg, 4 mol%), CuI (13 mg, 7mol%), 18d (140 
mg, 1.5 mmol) and 20a (174 mg, 1.5 mmol), 21m (146 mg, 
45%) was isolated as white crystalline solid, m.p. 74°C-76 °C. 
1H NMR (300 MHz, CDCl3): δ =  0.84 (t, J = 7.05Hz, 3H, 
CH3), 1.31-1.34 (m, 4H, 2CH2), 1.55- 1.62 (m, 2H, CH2), 3.06 
(t, J = 8.88 Hz, 2H, CH2), 3.86 (s, 3H, OCH3), 7.24-7.29 (m, 
2H, ArH), 7.40-7.45 (m, 1H, ArH), 7.85 (s, 1H, ArH), 7.99 (d, J = 8.07 Hz, 1H, ArH), 
8.79 (s, 1H, ArH). 13C NMR (300 MHz, CDCl3): δ = 14.0 (CH3), 22.5, 31.2, 31.9, 35.0 
(CH2), 52.2 (OCH3), 117.2 (C), 117.9 (CH), 118.8 (C), 123.2, 123.8, 124.6 (CH), 130.0 
(C), 131.3, 133.7 (CH), 137.0, 151.9,  152.0 (C), 160.4, 166.3 (CO). IR (ATR, cm-1): ν 
= 2954 (w), 2929 (w), 2855 (w), 1727 (s), 1609 (s), 1227 (s), 1184 (s), 1071 (m), 750 
(s). GC-MS (EI, 70 eV): m/z (%) = 324 ([M] +, 77), 293 (100), 268 (52), 249 (47), 237 
(25), 152 (16). HRMS (EI): calcd. for C20H20O4 ([M]
+): 324.13561. Found: 324.13529. 
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Methyl 6-oxo-9-pentyl-6H-benzo[c]chromene-8-carboxylate (21n): Starting with 1 
(200 mg, 1.0 mmol), K2CO3 (200 mg, 1.5 equiv.), 
PdCl2(PPh3)2(28 mg, 4 mol%), CuI (13 mg, 7mol%), 18d 
(140 mg, 1.5 mmol) and 20b (200 mg, 1.5 mmol), 21n (150 
mg, 44%) was isolated as brownish solid, m.p. 78°C-80 °C. 
1H NMR (300 MHz, CDCl3): δ =  0.84 (t, J = 7.24Hz, 3H, 
CH3), 1.32-1.38 (m, 6H, 3CH2), 1.56-1.66 (m, 2H, CH2), 
3.08 (t, J =7.95 Hz, 3H, CH3), 4.34 (q, J = 7.24, 2H, OCH2), 
7.26-7.31 (m, 2H, ArH), 7.42-7.48 (m, 1H, ArH), 7.89 (s, 1H, ArH),  8.00 (d, J = 8.16, 
1H, ArH), 8.81 (s, 1H, ArH). 13C NMR (300 MHz, CDCl3): δ = 14.0, 14.2 (CH3), 22.5, 
31.3, 31.9, 35.0, (CH2), 61.3 (OCH2), 117.3 (C), 117.9 (CH), 118.8 (C), 123.2, 123.8, 
124.6 (CH), 130.6 (C), 131.3, 133.5 (CH), 136.8, 151.8  151.9 (C), 160.5, 166.1 (CO). 
IR (ATR, cm-1): ν = 2957 (w), 2930 (w), 2856 (w), 1733 (s), 1614 (s), 1226 (s), 1181 
(s), 1070 (m), 747 (s). GC-MS (EI, 70 eV): m/z (%) = 338 ([M] +, 82), 293 (100), 
282(40), 249 (44), 267 (37), 254 (29). HRMS (EI): calcd. for C21H22O4 ([M]
+): 
338.15126. Found: 338.15117. 
Methyl 9-(4-tert-butylphenyl)-6-oxo-6H-benzo[c]chromene-8-carboxylate (21o): 
Starting with 1 (200 mg, 1.0 mmol), K2CO3 (200 mg, 1.5 
equiv.), PdCl2(PPh3)2(28 mg, 4 mol%), CuI (13 mg, 7mol%), 
18e (158 mg, 1.5 mmol) and 20a (174 mg, 1.5 mmol), 21o 
(190mg, 50%) was isolated as white crystalline solid, m.p. 
223°C - 225 °C.  1H NMR (300 MHz, CDCl3): δ = 1.30 (s, 9H, 
3CH3), 3.66 (s, 3H, OCH3), 7.22-7.30 (m, 4H, ArH), 7.39-7.46 
(m, 3H, ArH), 7.95-7.99 (m, 2H, ArH), 8.75 (s, 1H, ArH). 13C 
NMR (250 MHz, CDCl3): δ = 30.3 (3CH3), 33.6 (C), 51.3 (OCH3), 116.2 (C), 116.9 
(CH), 118.5 (C), 122.2, 123.3, 123.7 (CH), 124.3, 126.9 (2CH), 130.2 (C), 130.4, 131.7 
(CH), 135.6, 135.8, 147.7, 150.4 150.9 (C), 159.2, 166.2 (CO). IR (ATR, cm-1): ν = 
2956 (w), 2904 (w), 1722(s), 1611 (s), 1255 (m), 1228 (m), 1183 (m) 1084(m), 977 
(m), 836 (m), 754 (s). GC-MS (EI, 70 eV): m/z (%) = 386 ([M]+, 26),371 (100), 299 
(8),252 (10), 171 (7). HRMS (EI): calcd. for C25H22O4 ([M]
+): 386.15126. Found: 
386.15095. 
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Ethyl 9-(4-tert-butylphenyl-6-oxo-6H-benzo[c]chromene-8-carboxylate (21p): 
Starting with 1 (200 mg, 1.0 mmol), K2CO3 (200 mg, 1.5 
equiv.), PdCl2(PPh3)2 (28 mg, 4 mol%), CuI (13 mg, 
7mol%), 18e (158 mg, 1.5 mmol) and 20b (200 mg, 1.5 
mmol), 21p (190 mg, 47%) was isolated as white crystalline 
solid, m.p. 244 °C. 1H NMR (250 MHz, CDCl3): δ =  1.00 (t, 
J = 7.50 Hz, 3H, CH3), 1.31 (s, 9H, 3CH3), 4.10 (q,  J = 7.50 
Hz, 2H, OCH2), 7.23-7.33 (m, 4H, ArH), 7.39-7.49 (m, 3H, 
ArH), 7.97-8.01 (m, 2H, ArH), 8.76 (s, 1H, ArH). 13C NMR (250 MHz, CDCl3): δ = 
13.6 (CH3), 31.3 (3CH3), 34.6 (C), 61.4 (OCH2), 117.3 (C), 117.9 (CH), 119.6 (C), 
123.2, 124.1, 124.7 (CH), 124.7, 127.9 (2CH), 131.4 (CH), 132.0 (C), 132.6 (CH), 
136.5, 137.1, 148.6, 151.4 151.9(C),  160.3, 167.0 (CO). IR (ATR, cm-1): ν = 2957 (w), 
2902 (w), 1709 (s), 1611(s), 1251 (m), 1229 (m), 1184 (m) 1015(m), 838 (m), 761 (s). 
GC-MS (EI, 70 eV): m/z (%) = 400 ([M]+, 26), 385 (100), 299 (8), 252 (9), 14 (6),. 
HRMS (EI): calcd. for C26H24O4 ([M]
+): 400.16691. Found: 400.16711. 
Tert-butyl 9-(4-tert-butylphenyl)-6-oxo-6H-benzo[c]chromene-8-carboxylate (21q): 
Starting with 1 (200 mg, 1.0 mmol), K2CO3 (200 mg, 1.5 
equiv.), PdCl2(PPh3)2(28 mg, 4 mol%), CuI (13 mg, 
7mol%), 18e (158 mg, 1.5 mmol) and 20e (200 mg, 1.5 
mmol), 21q (198 mg, 45%) was isolated as white crystalline 
solid, m.p. 241-243 °C. 1H NMR (300 MHz, CDCl3): δ= 
1.22 (s, 9H, 3CH3), 1.31 (s, 9H, 3CH3), 7.25-7.33 (m, 4H, 
ArH), 7.39-7.47 (m, 3H, ArH), 7.96-7.99 (m, 2H, ArH), 8.69 
(s, 1H, ArH). 13C NMR (300 MHz, CDCl3): δ =  26.5, 30.3 (3CH3), 33.6,81.1, 116.4 
(C), 116.9 (CH), 18.6 (C), 122.2, 122.8, 123.6 (CH), 124.2, 127.1 (2CH), 130.2 (CH), 
130.3 (C), 131.2 (CH), 135.0, 136.4, 147.1, 150.3, 150.8(C),  159.4, 165.4 (CO). IR 
(ATR, cm-1): ν = 2962 (w), 2931 (w), 1729 (s), 1705 (s), 1611(s), 1251 (m), 1367 (m), 
1257 (s), 1157 (s), 1184 (m), 1084(m), 840 (m), 759 (s). GC-MS (EI, 70 eV): m/z (%) 
= 428 ([M]+, 13), 372 (79), 357 (100), 328 (35), 299 (27), 252 (18). HRMS (EI): calcd. 
for C28H28O4 ([M]
+): 428.19821. Found: 428.19877. 
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Allyl 9-(4-tert-butylphenyl)-6-oxo-6H-benzo[c]chromene-8-carboxylate (21r): 
Starting with 1 (200 mg, 1.0 mmol), K2CO3 (200 mg, 1.5 
equiv.), PdCl2(PPh3)2(28 mg, 4 mol%), CuI (13 mg, 
7mol%), 18e (158 mg, 1.5 mmol) and 20f (200 mg, 1.5 
mmol), 21r (182 mg, 44%) was isolated as white 
crystalline solid, m.p. 206-208 °C. 1H NMR (300 MHz, 
CDCl3): δ = 1.30 (s, 9H, 3CH3), 4.53 (d,  J = 6.0 Hz, 2H, 
OCH2), 5.03-5.09 (m, 2H, CH2), 5.51-5.69 (m, 1H, CH), 
7.25-7.32 (m, 4H, ArH), 7.39-7.44 (m, 3H, ArH), 7.96-8.00 (m, 2H, ArH), 8.77 (s, 1H, 
ArH). 13C NMR (300 MHz, CDCl3): δ = 31.3 (3CH3), 34.7 (C), 66.1 (OCH2), 117.3 
(C), 118.0 (CH), 118.7 (CH2), 119.6 (C), 123.3, 124.2, 124.7, (CH) 125.3, 128.0 
(2CH), 131.3, 131.4, 132.8 (CH), 133.5, 136.6, 137.0, 148.6, 151.5, 152.0(C), 160.3, 
166.7 (CO). IR (ATR, cm-1): ν = 2953 (w), 2903, 2866 (w), 1731 (s), 1708 (s), 1610(s), 
1249 (m), 1227 (s), 1190 (m) 1084(m), 925(m), 839 (m), 760 (s). GC-MS (EI, 70 eV): 
m/z (%) = 412 ([M]+, 32), 397 (100), 299 (11), 252 (11), 156 (7),. HRMS (EI): calcd. 
for C27H24O4 ([M]
+): 412.16691. Found: 412.16714. 
Methyl 6-oxo-9-o-tolyl-6H-benzo[c]chromene-8-carboxylate (21s): Starting with 1 
(200 mg, 1.0 mmol), K2CO3 (200 mg, 1.5 equiv.), 
PdCl2(PPh3)2(28 mg, 4 mol%), CuI (13 mg, 7mol%), 18f (174 
mg, 1.5 mmol) and 20a (174 mg, 1.5 mmol), 21s (152mg, 
44%) was isolated as white crystalline solid, m.p. 163-165 °C.  
1H NMR (250 MHz, CDCl3): δ = 2.36 (s, 3H, CH3), 3.67 (s, 
3H, OCH3), 7.09-7.20 (m, 3H, ArH), 7.24-7.34 (m, 3H, ArH), 
7.43-7.49 (m, 1H, ArH), 7.98-8.02 (m, 2H, ArH), 8.78(s, 1H, ArH). 13C NMR (250 
MHz, CDCl3): δ = 21.47 (CH3), 52.34 (OCH3), 117.26 (C), 118.00 (CH), 119.76 (C), 
123.34, 124.23, 124.78, 125.31, 128.22, 128.74, 129.11, (CH), 131.36 (C), 131.52, 
132.74 (CH), 136.69, 138.11, 139.90, 148.94, 151.99(C), 160.32, 167.17 (CO). IR 
(ATR, cm-1): ν = 2948 (w), 2918 (w), 1724 (s), 1605(s), 1229 (m), 1181 (m) 1082 (w), 
972 (m), 757 (s). GC-MS (EI, 70 eV): m/z (%) = 344 ([M]+, 95), 313 (100), 239 (22), 
226 (22), 269 (19), 113(10). HRMS (EI): calcd. for C22H16O4 ([M]
+): 344.10431. 
Found: 344.10410. 
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Methyl 6-oxo-9-(4-propylphenyl)-6H-benzo[c]chromene-8-carboxylate (21t): Starting 
with 1 (200 mg, 1.0 mmol), K2CO3 (200 mg, 1.5 equiv.), 
PdCl2(PPh3)2 (28 mg, 4 mol%), CuI (13 mg, 7mol%), 18g (200 
mg, 1.5 mmol) and 20a (174 mg, 1.5 mmol), 21t (174mg, 
44%) was isolated as white crystalline solid m.p. 146 °C-148 
°C. 1H NMR (300 MHz, CDCl3): 0.91 (t, J = 7.41 Hz, 3H, 
CH3), 1.63 (sext, J = 7.41 Hz 2H, CH2), 2.59 (t,  J = 7.41 Hz, 
2H, CH2), 3.65 (s, 3H, OCH3), 7.17-7.31 (m, 4H, ArH), 7.41-
7.47 (m, 3H, ArH), 7.96-7.99 (m, 2H, ArH) 8.75 (s, 1H, ArH). 13C NMR (250 MHz, 
CDCl3): δ = 13.8 (CH3), 24.4 (CH2), 37.7 (CH2) 52.3 (OCH3), 117.2 (C), 117.9 (CH), 
119.6 (C), 123.3, 124.2, 124.7 (CH), 128.0, 128.4 (2CH), 131.3 (C), 131.4, 132.7 (CH), 
136.6, 137.1, 139.9, 143.0 151.9(C), 160.3, 167.2 (CO). IR (ATR, cm-1): ν = 2949 (w), 
2929 (w), 2869 (w), 1715 (s), 1610(s), 1451 (m), 1430 (m), 1227 (s), 1187 (m) 1087 
(m), 980 (m), 749(s). GC-MS (EI, 70 eV): m/z (%) = 372 ([M]+, 64), 343 (100), 299 
(10), 239 (15), 226 (14), 171 (4). HRMS (EI): calcd. for C24H20O4 ([M]
+): 372.13561. 
Found: 372.13521. 
Methyl 9-(4-fluorophenyl)-6-oxo-6H-benzo[c]chromene-8-carboxylate (21u): 
Starting with 1 (200 mg, 1.0 mmol), K2CO3 (200 mg, 1.5 
equiv.), PdCl2(PPh3)2 (28 mg, 4 mol%), CuI (13 mg, 7mol%), 
18h (180 mg, 1.5 mmol) and 20a (174 mg, 1.5 mmol), 21u (185 
mg, 54%) was isolated as off-white crystalline solid, m.p. 187°C 
-189 °C. 1H NMR (300 MHz, CDCl3): δ = 3.68 (s, 3H, OCH3), 
7.05-7.13 (t, J = 8.64 Hz, 2H, ArH), 7.25-7.33 (m, 4H, ArH), 
7.44-7.49 (m, 1H, ArH), 7.96-8.00 (m, 2H, ArH), 8.80 (s, 1H, 
ArH). 19F NMR (282 MHz, CDCl3): δ = -113.36 (s, ArF). 
13C NMR (250 MHz, 
CDCl3): δ = 52.4 (OCH3), 115.4 (d, JC,F = 21.4 Hz, 2CH ), 117.07 (C), 118.03 (CH), 
119.98 (C), 123.32, 124.35, 124.83 (CH), 129.95 (d, JC,F = 8.2 Hz, 2CH), 131.02, 
131.68 (CH), 136.40 (d, JC,F = 3.7 Hz, C), 136.85 (C), 147.86, 152.01, 159.32 (C), 
160.17 (CO), 162.84 (d, JC,F = 248.4 Hz, CF), 166.79 (CO). IR (ATR, cm
-1): ν = 3077 
(w), 2959 (w), 1727 (s), 1604 (s), 1514 (m), 1229 (s), 1185 (s) 1090 (m), 912 (m), 830 
(m), 748 (s). GC-MS (EI, 70 eV): m/z (%) = 348 ([M]+, 89), 317 (100), 289 (8), 273 
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(20), 244 (30), 231 (18). HRMS (EI): calcd. for C21FH13O4 ([M]
+): 348.07924. Found: 
348.07917. 
Ethyl 9-(4-fluorophenyl)-6- oxo-6H-benzo[c]chromene-8-carboxylate (21v): Starting 
with 1 (200 mg, 1.0 mmol), K2CO3 (200 mg, 1.5 equiv.), 
PdCl2(PPh3)2(28 mg, 4 mol%), CuI (13 mg, 7mol%), 18h 
(180 mg, 1.5 mmol) and 20b (200 mg, 1.5 mmol), 21v (188 
mg, 54%) was isolated as off-white crystalline solid, m.p. 
193°C. 1H NMR (300 MHz, CDCl3): 1.09 (t, J = 6.9 Hz, 3H, 
CH3), 1.31, 4.13 (q, J = 6.9 Hz, 2H, OCH2), 7.04-7.12 (m, 
2H, ArH), 7.24-7.32 (m, 4H, ArH), 7.43-7.48 (m, 1H, ArH), 
7.95-7.97 (m, 2H, ArH), 8.78 (s, 1H, ArH). 19F NMR (282 MHz, CDCl3): δ = -113.50 
(s, ArF). 13C NMR (250 MHz, CDCl3): δ = 13.8 (CH3), 52.4 (OCH2), 115.3 (d, JC,F = 
21.4 Hz, 2CH ), 117.1 (C), 118.0 (CH), 119.9 (C), 123.3, 124.2 (CH), 124.5 (C), 124.8 
(CH), 129.9 (d, JC,F = 8.2 Hz, 2CH), 131.6, 132.8 (CH), 136.1 (d, JC,F = 3.7 Hz, C), 
136.7, 147.8 151.9 (C), 160.1 (CO), 162.8 (d, JC,F = 248.4 Hz, CF). 166.4 (CO). IR 
(ATR, cm-1): ν = 2989 (w) 2910 (w), 1720 (s), 1604 (s), 1514 (m), 1216 (s), 1183 (s) 
1088(m), 932(m), 839 (m), 743 (s). GC-MS (EI, 70 eV): m/z (%) = 362 ([M]+, 75), 317 
(100), 289 (11), 273 (19), 244 (31), 231 (19). HRMS (EI): calcd. for C22FH15O4 ([M]
+): 
362.09489. Found: 362.09481. 
Methyl 9-(4-methoxyphenyl)-6-oxo-6H-benzo[c]chromene-8-carboxylate (21w): 
Starting with 1 (200 mg, 1.0 mmol), K2CO3 (200 mg, 1.5 
equiv.), PdCl2(PPh3)2(28 mg, 4 mol%), CuI (13 mg, 7mol%), 
18i (180 mg, 1.5 mmol) and 20a (174 mg, 1.5 mmol), 21v (198 
mg, 55%) was isolated as white crystalline solid, m.p. 193 °C.  
1H NMR (300 MHz, CDCl3): δ = 3.68 (s, 3H, OCH3), 3.79 (s, 
3H, OCH3), 6.89-6.94 (m, 2H, ArH), 7.22-7.29 (m, 4H, ArH), 
7.41-7.46 (m, 1H, ArH), 7.96-7.99 (m, 2H, ArH), 8.72 (s, 1H, 
ArH). 13C NMR (250 MHz, CDCl3): δ = 52.38, 55.33 (OCH3), 113.88 (2CH), 117.24 
(C), 117.95 (CH), 119.41 (C), 123.28, 124.11, 124.75 (CH), 129.51 (2CH), 131.26 (C), 
131.46 (CH), 132.08 (C), 132.77 (CH), 136.63, 148.37, 151.94, 159.86(C), 160.31, 
167.37 (CO). IR (ATR, cm-1): ν = 2951 (w), 2835 (w), 1712 (s), 1607(s), 1226 (s), 
O O
O
O
F
O O
O
O
O
- 86 - 
 
1178 (m) 1088(m), 832 (m), 748 (s). GC-MS (EI, 70 eV): m/z (%) = 360 ([M] +, 100), 
329 (65), 286 (8), 242 (11), 213 (9). HRMS (EI): calcd. for C22H16O5 ([M]
+): 
360.09923. Found: 360.09909. 
Ethyl 9-(4-methoxyphenyl)-6-oxo-6H-benzo[c]chromene-8-carboxylate (21x): 
Starting with 1 (200 mg, 1.0 mmol), K2CO3 (200 mg, 1.5 
equiv.), PdCl2(PPh3)2(28 mg, 4 mol%), CuI (13 mg, 7mol%), 
18i (180 mg, 1.5 mmol) and 20b (200 mg, 1.5 mmol), 21x 
(202 mg, 55%) was isolated as white crystalline solid, m.p. 
152 °C-154 °C. 1H NMR (300 MHz, CDCl3): δ = 1.09 (t, J = 
7.14 Hz, 3H, CH3),  3.79 (s, 3H, OCH3),4.13 (q, J = 7.14 Hz, 
2H, OCH2), 7.06-7.12 (m, 2H, ArH), 7.24-7.32 (m, 4H, 
ArH), 7.43-7.48 (m, 1H, ArH), 7.95-8.00 (m, 2H, ArH), 8.78 (s, 1H, ArH). 13C NMR 
(250 MHz, CDCl3): δ = 13.93 (CH3), 55.36 (OCH3), 61.50 (OCH2), 113.84 (2CH), 
117.28 (C), 117.94 (CH), 119.41 (C), 123.27, 124.03, 124.74 (CH), 129.54 (2CH), 
131.85 (C), 131.46 (CH), 132.26 (C), 132.59 (CH), 136.493, 148.30, 151.92 159.86 
(C), 160.35, 167.04 (CO). IR (ATR, cm-1): ν = 2976 (w), 2836 (w), 1715 (s), 1606(s), 
1226 (s), 1177 (m) 1088 (m), 835 (m), 750 (s). GC-MS (EI, 70 eV): m/z (%) = 374 
([M]+, 100), 329 (68), 286 (8), 242 (12), 202 (13),. HRMS (EI): calcd. for C23H18O5 
([M]+): 374.11488. Found: 374.11521. 
8 - methyl-10-phenylchromeno[4,3- b]pyrazolo[4,3-e]pyridine-6(10H)-one (27a): 
 Starting with 1 (200 mg, 1.0 mmol), 25 (207 mg, 1.2 mmol), 
AlCl3 (3equiv. 400 mg, 3.0 mmol) in 10-15 mL dry MeOH. The 
reaction mixture was refluxed under moisture free environment 
for 8-10 hrs. The precipitates formed were directly filtered washed 
with cold MeOH. The precipitate were re-dissolved in hot MeOH, 
and filtered again. Two filtrates obtained were combined, 
adsorbed on silica gel and purified by chromatography using two solvent systems 
(silica gel, n-heptane/EtOAc = 3:2 and chloroform/n-heptane = 9:1), 27a (202 mg, 
62%) was isolated as white crystalline solid, m.p. 240 °C - 241 °C.1H NMR (300 MHz, 
CDCl3): δ = 2.5 (s, 3H, CH3), 7.25 - 7.34 (m, 3H, ArH), 7.46 (m, 3H, ArH), 8.26 - 8.29 
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(m, 2H, ArH), 8.49 (dd, J = 7.91 Hz, 1.57 Hz, 1H, ArH), 8.89 (s, 1H, ArH).13CNMR 
(300MHz, CDCl3): δ = 12.5 (CH3), 111.7 (C), 117.2 (CH), 117.9, 119.4 (C), 120.7 
(2CH), 124.8, 125.1, 126.1 (CH), 129.1 (2CH), 132.5, 133.9 (CH), 138.9, 145.0, 150.9, 
151.8, 152.7 (C), 161.5 (CO). IR (ATR, cm-1): ν = 1719 (s), 1607 (m), 1590 (m), 1497 
(s), 1487 (s), 1419 (m), 1384 (m), 1336 (w), 1251 (m), 1243 (m), 1187 (m), 1115 (m), 
1089 (m), 908 (m), 752 (s). GC-MS (EI, 70 eV): m/z (%) = 327 ([M] +, 100), 326 (25), 
328 (21), 77 (12) 312 (11). HRMS (EI): calcd. for C20H13N3O2 ([M+]
+): 327.10023. 
Found:327.09982. 
Tert-butyl-5-(4-chloro-2H-chromen-3-yl)methyleneamino)-1H-pyrrole-3-carbonitrile 
(28a): Starting with 2 (194 mg, 1.0 mmol) and 22a (196 mg, 
1.2 mmol) dissolved in 10 mL of dry DMF. After addition of 1 
mL of TMSCL, the reaction mixture was stirred at 120 °C for 
10 hrs. Workup procedure (a): The mixture was poured into ice 
water. The resulting yellow precipitates were filtered and dried. 
To remove minute inorganic impurities the precipitates were 
dissolved in ethyl acetate-water (2:1 by volume). The organic layer was dried and 
evaporated to get final product as yellow crystalline solid. Workup procedure (b): Half 
of the volume of DMF was evaporated and the reaction mixture was allowed to stand 
for several hrs. Precipitates formed were filtered, washed with cold MeOH and dried to 
give 28a (260mg, 76%)  as yellow crystalline solid, m.p. 232°C-233 °C. 1H NMR (300 
MHz, CDCl3): δ = 1.58 (s, 9H, 3CH3), 5.14 (s, 2H, CH2), 6.42 (d, J = 1.8 Hz, 1H, 
ArH), 6.82 (dd, J = 8.1 Hz, J = 1.1 Hz, 1H, ArH), 6.95 (td, J = 7.6 Hz, J = 1.1 Hz, 1H, 
ArH), 7.18-7.23 (m, 2H, ArH), 7.54 (dd, J = 7.8 Hz, J = 1.4 Hz, 1H, ArH). 8.54 (s, 1H, 
ArH). 13CNMR (62.8 MHz, CDCl3): δ = 30.0 (3CH3), 58.4 (C), 65.9 (OCH2), 90.9 (C), 
99.4, 116.1 (CH), 116.7, 121.3 (C), 122.0, 125.6 (CH), 125.7 (C), 125.8, 132.0 (CH), 
134.2, 142.7 (C), 149.1 (CH), 155.5 (C). IR (ATR, cm-1): ν = 3150 (w), 2977 (w), 2358 
(w) 2217 (s) 1601 (m), 1562 (m), 1530 (w), 1473 (m), 1455 (w), 1361 (m), 1295 (m), 
1203 (m), 1150 (m), 1085 (m), 1043 (m), 936 (w), 814 (s), 758 (s), 628 (s), 563 (m). 
GC-MS (EI, 70 eV): m/z (%) =339 ([M] +, 28), 248 (100), 247 (36), 246 (57), 57 (33), 
41(29).  HRMS (EI): calcd. for C19H18N3OCl ([M]
+): 339.11329.Found: 339.11295 and 
for C19H18N3
37OCl([M]+): 341.11034. Found: 341.11043. 
O
Cl N
N
CN
- 88 - 
 
10-tert-butyl-6,10-dihydrochromeno[4,3-b]pyrrolo[3,2-e]pyridine-8-carbonitrile 
(29a): Starting with 2 (194 mg, 1.0 mmol) and 22a (196 mg, 1.2 
mmol), AlCl3 (3equiv., 400mg, 3.0 mmol), 29a (85mg, 28%) 
was isolated as white crystalline solid. m.p. 189°C - 191°C. 1H 
NMR (300 MHz, CDCl3):δ = 1.80 (s, 9H, 3CH3), 5.24 (d, 0.9 
Hz, 2H, CH2), 6.92 (dd, J = 8.14 Hz, 1.05 Hz, 1H, ArH), 7.04 
(td, J = 7.54 Hz, 1.16 Hz, 1H, ArH), 7.21-7.27 (m, 1H, ArH), 7.68 (s, 1H, ArH), 7.75 
(s, 1H, ArH), 8.18 (dd, J = 7.76 Hz, 1.68 Hz, 1H, ArH). 13CNMR (250 MHz, CDCl3): δ 
= 29.1 (3CH3), 58.6 (C), 68.5 (OCH2), 83.3, 115.4 (C), 117.1 (CH), 120.4, 121.1 (C), 
122.2, 123.6 (CH), 123.7 (C), 124.7, 131.0, 133.2 (CH), 143.9, 147.1, 156.5 (C).IR 
(ATR, cm-1): ν = 2972 (w), 2214 (s), 1615 (m), 1587 (m), 1526 (m), 1414 (s), 1315 (s), 
1209 (s), 1170 (s), 1042 (m), 937 (w), 816 (w), 749 (s).GC-MS (EI, 70 eV): m/z (%) = 
303([M] +, 32), 247 (72), 246 (100),218 (11).HRMS (EI): calcd. for C19H17N3O ([M]
+): 
303.13661. Found: 303.13642 
10-(4-methoxybenzyl)-10H-benzo[h]pyrrolo[2,3-b][1,6]naphthyridine-8-carbonitrile 
(29b):Starting with 2 (194 mg, 1.0 mmol), 22b(272 mg, 
1.2 mmol), AlCl3 (3equiv., 400mg, 3.0 mmol), 29b (170 
mg, 46%) was isolated as white crystalline solid.m.p. 
156°C-158 °C. 1H NMR (300 MHz, CDCl3): δ = 3.71 (s, 
3H, OCH3), 5.25 (s, 2H, OCH2), 5.53 (s, 2H, NCH2), 6.80 
(d, J = 8.63 Hz, 2H, ArH), 6.93 (dd, J = 8.15 Hz, 0.85 Hz, 1H, ArH), 7.06 (td, J = 7.60 
Hz, 1.01 Hz, 1H, ArH), 7.20-7.29 (m, 3H, ArH), 7.54 (s, 1H, ArH), 7.70 (s, 1H, ArH), 
8.27 (dd, J = 7.77 Hz, 1.60 Hz, 1H, ArH). 13CNMR (75.4 MHz, CDCl3): δ = 48.3 
(NCH2), 55.3 (OCH3), 68.5 (OCH2), 84.9 (C), 114.4 (2CH), 117.1 (CH), 118.9, 121.8 
(C), 122.3 (CH), 123.4 (2C), 124.0, 124.7 (CH), 127.8 (C), 129.7 (2CH), 131.3, 134.6 
(CH), 145.2, 146.8, 156.6, 159.7 (C). IR (ATR, cm-1): ν = 2956 (w), 2913 (w), 2217 
(m), 1513 (s), 1456 (m), 1440 (m), 1381 (s), 1245 (s), 1180 (s), 1171 (s), 1026 (s), 850 
(m), 835 (m), 757 (s), 609 (m). GC-MS (EI, 70 eV): m/z (%) = 367 ([M] +, 24), 364 
(20), 121 (100), 122 (8), 91 (4). HRMS (EI): calcd. for C23H17N3O2 ([M]
+): 367.13153. 
Found: 367.13141. 
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10-cyclohexyl-6,10-dihydrochromeno[4,3-b]pyrrolo[3,2-e]pyridine-8-carbonitrile 
(29c): Starting with 2 (194 mg, 1.0 mmol), 22c (227 mg, 1.2 
mmol), AlCl3 (3equiv.,400 mg, 3.0 mmol), 29c (141mg, 43%) 
was isolated as white crystalline solid.  m.p. 198°C-200°C. 1H 
NMR (300 MHz, CDCl3): δ = 1.16-1.77 (m, 6H, 3CH2),  1.88 
(d, J = 13.04 Hz, 2H, CH2), 2.09 (d, J = 10.58 Hz, 2H, CH2), 
4.77 (tt, J = 11.80 Hz, 3.77 Hz, 1H, NCH), 5.22 (d, J = 0.8 Hz, 
2H, CH2), 6.90 (dd, J = 8.20 Hz, 1.02 Hz, 1H, ArH), (td, J = 7.51 Hz, 1.10 Hz, 1H, 
ArH), 7.23 (ddd, J = 8.11 Hz, 7.32 Hz, 1.72 Hz, 1H, ArH), 7.66 (s, 1H, ArH), 7.68 (s, 
1H, ArH), 8.22 (dd, J = 7.80 Hz, 1.66 Hz, 1H, ArH). 13CNMR (300 MHz, CDCl3): δ = 
25.4 (CH2), 25.7, 33.8 (2CH2), 54.5 (NCH), 68.6 (CH2), 84.2, 115.4 (C), 117.1 (CH), 
119.2, 121.7 (C), 122.3 (CH), 123.5 (C), 123.8, 124.7, 131.1, 132.6 (CH), 144.6, 146.4, 
156.6 (C). IR (ATR, cm-1): ν = 2931 (w), 2848 (w), 2217 (s), 1584 (w), 1526 (m), 1459 
(s), 1308 (m), 1257 (s), 1239 (s), 1173 (s), 1036 (s), 856 (m), 748 (s). GC-MS (EI, 70 
eV): m/z (%) = 329 ([M] +, 45), 247 (100), 246 (74), 248 (20), 245 (14). HRMS (EI): 
calcd. for C21H19N3O ([M]
+): 329.15226. Found: 329.15187. 
8-methyl-10-phenyl-6,10-dihydrochromeno[4,3-b]pyrazolo[4,3-e]pyridine (30): 
Starting with 2 (194 mg, 1.0 mmol), 25 (207 mg, 1.2 mmol), 
AlCl3 (3equiv.,400mg, 3.0 mmol), 30 (180mg, 58%) was isolated 
as white crystalline solid, m.p. 179°C-180 °C. 1H NMR (300 
MHz, CDCl3): δ = 2.41 (s, 3H, CH3), 5.08 (d, J = 0.88Hz, 2H, 
CH2), 6.84 (dd, J = 8.13, J = 1.05 Hz, 1H, ArH), 6.99 (td, J = 
7.57Hz, J = 1.1 Hz, 1H, ArH), 7.12-7.24 (m, 2H, ArH), 7.37-7.43 
(m, 3H, ArH), 8.17 (dd, 7.82 Hz, J = 1.66 Hz, 1H, ArH). 8.24-8.28 (m, 2H, ArH). 13C 
NMR (250 MHz, CDCl3): δ = 12.4 (CH3), 68.5 (CH2), 115.8 (C), 117.1 (2CH), 120.2 
(CH), 120.2 (C), 122.3 (CH), 123.2 (C), 124.8, 125.1, 125.5 CH), 128.9 (2CH), 131.7 
(CH), 139.7, 142.5, 148.3, 150.5, 157.1 (C). IR (ATR, cm-1): ν = 2917 (w), 2852 (w), 
1591 (m), 1562 (m), 1488 (m), 1473 (m), 1462 (w), 1388 (m), 1280 (w), 1249 (w), 
1122 (m), 1033 (m), 886 (w), 936 (w), 779 (m), 754 (s), 746 (s), 691 (m). GC-MS (EI, 
70 eV): m/z (%) = 313 ([M] +, 77), 312 (100), 271 (5), 77 (9), 51 (4). HRMS (EI): 
calcd. for C20H16N3O ([M+H]
+): 314.12899. Found 314.12879. 
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10-tert-butyl-10H-benzo[h]pyrrole[2,3-b][1,6]naphthyridine-8-carbonitrile (31a): 
Starting with 4 (190 mg, 1.0 mmol) and 22a (196 mg, 1.2 
mmol),  31a (101mg, 28%) was isolated as white crystalline 
solid. m.p. 239°C -241 °C.1H NMR (300 MHz, CDCl3):δ  = 
1.94 (s, 9H, 3CH3), 7.66-7.72 (m, 1H, ArH), 7.74-7.80 (m, 1H, 
ArH), 8.11 (s, 1H, ArH), 8.15 (d, J = 7.51 Hz, 1H, ArH), 8.63 
(s, 1H, ArH), 9.07 (dd, J = 8.03 Hz, 1.41 Hz, 1H, ArH), 9.32 (s, 1H, ArH). 13CNMR 
(300 MHz, CDCl3): δ = 28.1 (3CH3), 58.3, 83.3, 113.7, 116.3, 120.7 (C), 122.6 (CH), 
124.5 (C), 126.3, 127.2, 128.2, 129.1, 136.2 (CH), 143.8, 144.6, 147.8 (C), 152.1 
(CH).IR (ATR, cm-1): ν = 3571 (m), 3564 (m), 2222 (s), 1596 (m), 1522 (m), 1485 (w), 
1440 (w), 1399 (s), 1273 (m), 1187 (s), 934 (m), 785 (m), 766 (s). GC-MS (EI, 70 eV): 
m/z (%) = 300 ([M] +, 21), 244 (100), 245 (18), 243 (11), 217 (6), 189 (7). HRMS (EI): 
calcd. for C19H16N4 ([M]
+): 300.13695. Found: 300.13712. 
10-(4-methoxybenzyl)-10H-benzo[h]pyrrolo[2,3-b][1,6]naphthyridine-8-carbonitrile 
(31b): Starting with 4 (190 mg, 1.0 mmol), 22b (272 mg, 
1.2 mmol), 29b (190 mg, 52%) was isolated as white 
crystalline solid. m.p. 229°C -230 °C. 1H NMR (300 MHz, 
CDCl3): δ =  3.70 (s, 3H, OCH3), 5.53 (s, 2H, NCH2), 6.8 
(d, J = 8.6 Hz, 2H, ArH), 7.29 (d, J = 8.6 Hz, 2H, ArH), 
7.64-7.70 (m, 1H, ArH), 7.73-7.79 (m, 1H, ArH), 7.82 (s, 1H, ArH), 8.1 (dd, J = 8.16 
Hz, J = 0.78 Hz, 1H, ArH), 8.5 (s, 1H, ArH), 9.09 (dd, J = 7.98 Hz, 1.39 Hz, 1H, ArH). 
9.23 (s, 1H, ArH). 13C NMR (75.4 MHz, CDCl3): δ = 48.6 (CH2), 55.3 (OCH3), 85.7,  
114.3 (C), 114.6 (2CH), 117.9, 120.3 (C), 123.6 (CH), 125.1 (C), 127.2 (CH), 127.3 
(C), 128.5, 129.4 (CH), 129.9 (2 CH), 130.2, 138.5 (CH), 145.7 (C), 146.0 (C), 148.2 
(C), 153.2 (CH), 159.9 (C). IR (ATR, cm-1): ν = 2956 (w), 2913 (w), 2217 (m), 1513 
(s), 1456 (m), 1440 (m), 1381 (s), 1245 (s), 1180 (s), 1171 (s), 1026 (s), 850 (m), 835 
(m), 757 (s), 609 (m). GC-MS (EI, 70 eV): m/z (%) = 364 ([M] +, 20), 122 (8),121 
(100), 91 (4), 77 (7). HRMS (EI): calcd. for C23H16N4O([M]
+): 364.13186. Found: 
364.13187. 
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8-methyl-10-phenyl-10H-benzo[h]pyrozolo[3,4-b][1,6]naphthyridine (32): Starting 
with 4 (190 mg, 1.0 mmol), 25 (207 mg, 1.2 mmol), 32 (176mg, 
57%) was isolated as white crystalline solid,. m.p. 163°C -165 
°C. 1H NMR (300 MHz, CDCl3):δ  = 2.5 (s, 3H, CH3), 7.17-7.24 
(m, 1H, ArH), 7.42-7.49 (m, 3H, ArH), 7.60-7.65 (m, 1H, ArH), 
7.93 (dd, J = 8.07 Hz, 0.54 Hz, 1H, ArH), 8.14 (s, 1H, ArH), 
8.28-8.32 (m, 2H, ArH), 8.69 (dd, J = 8.10 Hz, 1.27 Hz, 1H, 
ArH), 8.93 (s, 1H, ArH).13C NMR (300 MHz, CDCl3): δ = 12.5 (CH3), 116.5, 117.7 
(C), 120.0 (2CH), 124.0 (CH), 124.9 (C), 125.4, 127.0 (CH), 128.9 (2CH), 129.03, 
130.1, 130.5 (CH), 139.4, 144.0, 146.2, 147.9, 150.5 (C), 153 (CH). IR (ATR, cm-1): ν 
= 1621 (w), 1589 (m), 1495 (m), 1439 (w), 1421 (w), 1341 (w), 1223 (w), 798 (m), 757 
(s), 750 (s), 659 (s). GC-MS (EI, 70 eV): m/z (%) = 310 ([M] +, 100), 309 (37), 295 
(12), 77 (11), 51 (7). HRMS (EI): calcd. for C20H14N4 ([M+]
+): 310.12130. Found: 
310.12062. 
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7 Crystallographic Data 
7.1 Crystal data and Structure refinement of compound 9a 
Identification code    ch_ma18 
Empirical formula    C18H14O6 
Formula weight    326.26 
Temperature    173 K 
Wavelength    0.71073 Å 
Crystal system    Triclinic,  
Space group (H.-M.)   Pī     
Space group (Hall)   -P 1 
Unit cell dimensions   a = 8.1722 (4) Å α = 113.294 (2)° 
      b = 9.0126 (4) Å β = 94.407 (2)° 
      c = 11.3331(5) Å γ = 104.568 (2)° 
Volume (Z)    2 
Density (calculated)   1.490 Mg m-3 
F(000)     340 
Crystal size    0.47 x 0.15 x 0.08 mm 
Θrange for data collection   5.0-60.1° 
Measured reflections   14504 
Independent reflections   4111    
Absorption correction   multi-scan 
Max. and min. transmission  0.949 and 0.990 
Refinement method   Full Least-square matrix on F2 
Goodness-of-fit on F2   1.09 
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7.2 Crystal data and Structure refinement of compound 9g’ 
Identification code   ch_ma19a 
Empirical formula    C17H14O4 
Formula weight    282.28 
Temperature    173 K 
Wavelength    0.71073 Å 
Crystal system    Monoclinic 
Space group (H.-M.)   P21/n 
Space group (Hall)   -P 2yn 
Unit cell dimensions   a = 7.0981 (2) Å β = 97.262 (1)° 
      b = 7.9858 (2) Å 
      c = 11.8633 940 Å  
Volume (Z)    4 
Density (calculated)   1.405 Mg m-3 
F(000)     592 
Crystal size    0.49 x 0.36 x 0.32 
Θrange for data collection   5.8-60.0° 
Measured reflections   14262    
Independent reflections   3867 
Absorption correction   multi-scan 
Max. and min. transmission  0.953 and 0.969 
Refinement method   Full Least-square matrix on F2 
Goodness-of-fit on F2   1.06 
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7.3 Crystal data and Structure refinement of compound 13 
Identification code    av_ma24 
Empirical formula    C16H12O3 
Formula weight    252.26 
Temperature    173 K 
Wavelength    0.71073 Å 
Crystal system    Triclinic 
Space group (H.-M.)   Pī 
Space group (Hall)   -P 1 
Unit cell dimensions   a = 7.3113 (2) Å α = 78.515 (1)° 
      b = 7.8569 (2) Å β = 83.383 (1)° 
      c = 11.8633 (4) Å γ = 64.034 (1)° 
Volume (Z)    2 
Density (calculated)   1.396 Mg m-3 
F(000)     264 
Crystal size     0.82 x 0.29 x 0.10 
Θrange for data collection   5.9-59.9° 
Measured reflections   12464    
Independent reflections   3457 
Max. and min. transmission  0.925 and 0.990 
Refinement method   Full Least-square matrix on F2 
Goodness-of-fit on F2   1.05 
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7.4 Crystal data and Structure refinement of compound 9c 
Identification code    is_ma23 
Empirical formula    C20H18O6 
Formula weight    354 
Temperature    173 K 
Wavelength    0.71073 Å     
Crystal system    Triclinic 
Space group (H.-M.)   Pī 
Space group (Hall)   -P 1 
Unit cell dimensions   a = 9.5118 (2) Å α = 68.412 (1)° 
      b = 9.6807 (2) Å β = 73.556 (1)° 
      c = 10.2910 (3) Å γ = 88.203 (1)° 
Volume (Z)    2 
Density (calculated)   1.397 Mg m-3 
F(000)     372      
Crystal size    0.48 x 0.28 x 0.08 
Θrange for data collection   4.5-64.9° 
Measured reflections   27837     
Independent reflections   6080 
Absorption correction   multi-scan 
Max. and min. transmission  0.952 and 0.992 
Refinement method   Full Least-square matrix on F2 
Goodness-of-fit on F2   1.04 
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7.5 Crystal data and Structure refinement of compound 14c 
Identification code    is_ma4_2 
Empirical formula    C20H20O5 
Formula weight    340.36 
Temperature    173 K 
Wavelength    0.71073 Å 
Crystal system    Monoclinic 
Space group (H.-M.)   P21/c 
Space group (Hall)   -P 2ybc 
Unit cell dimensions   a = 11.9410 (3) Å β = 113.094 (1)° 
      b = 12.7890 (4) Å 
      c = 12.0032 (3) Å  
Volume (Z)    4 
Density (calculated)   1.341 Mg m-3 
F(000)     720 
Crystal size    0.32 x 0.20 x 0.05 
Θrange for data collection   4.5-57.9° 
Measured reflections   24129 
Independent reflections   4907 
Absorption correction   multi-scan 
Max. and min. transmission  0.970 and 0.995 
Refinement method   Full Least-square matrix on F2 
Goodness-of-fit on F2   1.02 
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7.6 Crystal data and Structure refinement of compound 17b 
Identification code    ah_ma_4_16_2 
Empirical formula    C25H22O6 
Formula weight    418.43 
Temperature    173 K 
Wavelength    0.71073 Å 
Crystal system    Triclinic 
Space group (H.-M.)   Pī 
Space group (Hall)   -P 1 
Unit cell dimensions   a = 5.8372 (2) Å β = 90.372 (2)° 
      b = 11.6055 (2) Å 
      c = 15.6114 (4) Å 
Volume (Z)    2      
Density (calculated)   1.337 Mg m-3 
F(000)     440 
Crystal size    0.44 x 0.24 x 0.19 
Θrange for data collection   2.7-32.6° 
Measured reflections   35203 
Independent reflections   7505 
Absorption correction   multi-scan 
Max. and min. transmission  0.959 and 0.982 
Refinement method   Full Least-square matrix on F2 
Goodness-of-fit on F2   1.02 
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7.7 Crystal data and Structure refinement of compound 17f 
Identification code    Ch_ma35 
Empirical formula    C21H14O4 
Formula weight    330.32 
Temperature    173 K 
Wavelength    0.71073 Å 
Crystal system    Monoclinic 
Space group (H.-M.)   P21/c 
Space group (Hall)   -P 2ybc 
Unit cell dimensions   a = 12.1411 (11) Å β = 100.638 (6)° 
      b = 14.7612 (15) Å 
      c = 8.7159 (8) Å  
Volume (Z)    4 
Density (calculated)   1.429 Mg m-3 
F(000)     688 
Crystal size    0.37 x 0.16 x 0.06 
Θrange for data collection   5.5-63.4° 
Measured reflections   15702 
Independent reflections   4060 
Absorption correction   multi-scan 
Max. and min. transmission  0.964 and 0.994 
Refinement method   Full Least-square matrix on F2 
Goodness-of-fit on F2   1.09 
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7.8 Crystal data and Structure refinement of compound 28a 
Identification code    is_mafcr03 
Empirical formula    C19H18ClN3O 
Formula weight    339.81 
Temperature    173 K 
Wavelength    0.71073 Å 
Crystal system    Orthorhombic 
Space group (H.-M.)   P212121 
Space group (Hall)   P 2ac 2ab 
Unit cell dimensions   a = 6.4919 (5) Å  
      b = 7.7941 (6) Å 
      c = 33.820 (3) Å  
Volume (Z)    4 
Density (calculated)   1.319 Mg m-3 
F(000)     712 
Crystal size    0.57 x 0.14 x 0.04     
Θrange for data collection   4.8-50.2° 
Measured reflections   18987 
Independent reflections   5304 
Absorption correction   multi-scan 
Max. and min. transmission  0.878 and 0.991 
Refinement method   Full Least-square matrix on F2 
Goodness-of-fit on F2   1.03 
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7.9 Crystal data and Structure refinement of compound 30 
Identification code    is_fcr6b 
Empirical formula    C20H15N3O 
Formula weight    313.35 
Temperature    173 K 
Wavelength    0.71073 Å    
Crystal system    Monoclinic 
Space group (H.-M.)   P21/c 
Space group (Hall)   -P 2ybc 
Unit cell dimensions   a = 7.2639 (4) Å β = 95.886 (3)° 
      b = 10.0858 (6) Å 
      c = 20.6740 (11) Å 
Volume (Z)    4 
Density (calculated)    1.381 Mg m-3 
F(000)     656 
Crystal size    0.49 x 0.10 x 0.07 
Θrange for data collection   5.6-51.3° 
Measured reflections   16019 
Independent reflections   4374 
Absorption correction   multi-scan 
Max. and min. transmission  0.958 and 0.994 
Refinement method   Full Least-square matrix on F2 
Goodness-of-fit on F2   1.01 
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7.10 Crystal data and Structure refinement of compound 31b 
Identification code    is_fp01 
Empirical formula    C23H16N4O 
Formula weight    364.40 
Temperature    173 K 
Wavelength    0.71073 Å     
Crystal system    Monoclinic 
Space group (H.-M.)   P21/n 
Space group (Hall)   -P 2yn 
Unit cell dimensions   a = 12.6335 (13) Å β = 95.092 (6)° 
      b = 6.9137 (7) Å 
      c = 20.278 (2) Å 
Volume (Z)    4 
Density (calculated)   1.372 Mg m-3 
F(000)     760 
Crystal size    0.99 x 0.24 x 0.03 
Θrange for data collection   6.5-60.8° 
Measured reflections   17985     
Independent reflections   4474 
Absorption correction   multi-scan 
Max. and min. transmission  0.919 and 0.997 
Refinement method   Full Least-square matrix on F2 
Goodness-of-fit on F2   1.02 
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